People's Democratic Republic of Algeria
Ministry of Higher Education and Scientific Research
Mohamed El Bachir El Ibrahimi University of Bordj Bou Arréridj
Faculty of Mathematics and Computer Science
Computer Science Department

DISSERTATION
Presented in fulfillment of the requirements of obtaining the degree
Master in Computer Science
Network and Multimedia

THEME

AI-Driven Prescription Safety System

Presented by:
Aymen BOUREGHDA
Houssam karam eddine BOUKHARI
Taha Yacine BENDERRADJI
Oussama BENMEHAMED

Publicly defended on: 08/10/2025
In front of the jury composed of:
Dr. Nadjib BENAOUDA
Dr. Oussama SENOUCI
Supervisor 1: Dr. Meriem LAIFA
Supervisor 2: Dr. Abdallah BENGUEDDOUDJ

2024/2025

Dedications

This work is dedicated to our families, who believed in us and provided the foundation that made this journey possible. To our professors and mentors who challenged us to think beyond conventional solutions and guided us toward meaningful innovation. To the healthcare workers of Algeria who inspired this project through their daily commitment to patient care despite systemic challenges. To our fellow students who shared knowledge, offered encouragement, and reminded us that the best solutions emerge from collaboration. And finally, to the patients whose safety and well-being motivated every line of code we wrote—may this small contribution help build a healthier future for Algeria.

Acknowledgments

We would like to express our sincere gratitude to all those who contributed to the successful completion of this dissertation. First and foremost, we extend our deepest appreciation to our supervisors, Dr. Abdallah BENGUEDDOUDJ and Dr. Meriem LAIFA, whose expertise and dedication were fundamental to this research. They provided the strategic vision that shaped our project's direction, helping us clarify our research objectives and establish a clear methodological framework. They demonstrated exceptional patience with our learning process, offered constructive feedback that elevated our work, and remained available whenever challenges arose. Their mentorship was instrumental in transforming our initial concept into a comprehensive research contribution.

We are deeply grateful to our families, who believed in us and provided the foundation that made this journey possible. Their support and understanding were crucial throughout this demanding academic endeavor, and their encouragement during challenging moments helped us maintain focus and determination to complete this work.

We also thank our fellow students and colleagues who contributed to our research through constructive feedback and technical discussions that helped refine our approach and methodology.

Our sincere thanks go to the members of the examination committee for taking the time to evaluate our work and provide valuable feedback that will undoubtedly enhance the quality and impact of this research.

Abstract

Drug-drug interactions (DDIs) present a critical challenge in Algeria's healthcare system due to fragmented practices and limited digital infrastructure, contributing to medication errors and adverse outcomes. MolePure, an AI-driven prescription safety system, tackles these issues with an integrated ecosystem offering DDI detection at all stages—doctor prescribing, pharmacist dispensing, and patient monitoring. It features a mobile app for patients to track medications, desktop apps for doctors to manage prescriptions with real-time DDI alerts, and for pharmacists to ensure safe dispensing, all linked via interoperable APIs prioritizing security and usability. An AI model, utilizing machine learning and deep learning, enhances interaction prediction, reducing errors and supporting digital health growth. By fostering collaboration across stakeholders, MolePure improves patient safety, streamlines workflows, and promotes safer pharmaceutical practices, aiming to decrease adverse events and elevate care quality in Algeria's evolving healthcare landscape.

Keywords: AI-driven system, prescription safety, drug-drug interactions, DDI detection, healthcare ecosystem, Algerian healthcare.

Résumé

Les interactions médicamenteuses (IM) représentent un défi majeur dans le système de santé algérien, où des pratiques fragmentées et une infrastructure numérique limitée entraînent des erreurs médicamenteuses et des effets indésirables. MolePure, un système de sécurité des prescriptions piloté par l'IA, répond à ces problèmes en proposant un écosystème intégré offrant une détection des IM à toutes les étapes : prescription par les médecins, dispensation par les pharmaciens et suivi par les patients. Ce système inclut une application mobile pour les patients afin de suivre leurs traitements, des applications de bureau pour les médecins pour gérer les prescriptions avec des alertes en temps réel, et pour les pharmaciens pour assurer une dispensation sécurisée, le tout connecté via des API interopérables privilégiant la sécurité et la facilité d'utilisation. Un modèle d'IA, basé sur l'apprentissage automatique et profond, améliore la prédiction des interactions, réduisant les erreurs et soutenant l'évolution de la santé numérique. En favorisant la collaboration entre les parties prenantes, MolePure vise à améliorer la sécurité des patients, optimiser les flux de travail et promouvoir des pratiques pharmaceutiques plus sûres, contribuant ainsi à diminuer les incidents indésirables et à élever la qualité des soins en Algérie.

Mots-clés : système piloté par IA, sécurité des prescriptions, interactions médicamenteuses, détection des IM, écosystème de santé, santé en Algérie.

ملخص

تشكل التفاعلات الدوائية (DDIs) تحديا كبيرا في نظام الرعاية الصحية في الجزائر بسبب الممارسات المنفصلة والبنية التحتية الرقمية المحدودة، مما يؤدي إلى أخطاء الأدوية والنتائج السلبية. يقدم MolePure، وهو نظام أمان وصفات طبية مدعوم بالذكاء الاصطناعي، حلاً يتكون من نظام متكامل يوفر الكشف عن التفاعلات الدوائية في جميع المراحل: عند وصف الطبيب، توزيع الصيدلي، ومراقبة المريض. يشمل الحل تطبيقا محمولا للمرضى لتتبع الأدوية، وتطبيقات سطح المكتب للأطباء لإدارة الوصفات مع تنبيهات التفاعل الفورية، وللصيادلة لضمان التوزيع الآمن، مع ربط كل ذلك عبر واجهات برمجية تطبيقية (APIs) تُركز على الأمان والأداء. يعتمد نموذج الذكاء الاصطناعي، باستخدام تقنيات التعلم الآلي والتعلم العميق، على التنبؤ بالتفاعلات لتعزيز السلامة، مما يقلل من الأخطاء ويدعم نمو الصحة الرقمية. من خلال تعزيز التعاون بين الأطراف المعنية، يسعى MolePure إلى تحسين سلامة المرضى، تبسيط سير العمل لمقدمي الرعاية الصحية، وتعزيز الممارسات الصيدلانية الآمنة، بهدف تقليل الحوادث السلبية ورفع جودة الرعاية في المنظومة الصحية الجزائرية .

الكلمات المفتاحية: نظام مدعوم بالذكاء الاصطناعي، أمان الوصفات الطبية، التفاعلات الدوائية، كشف التفاعلات الدوائية، نظام بيئي صحي، الرعاية الصحية الجزائرية.

Contents

List of Figures

List of Tables

General Introduction

The Persistent Challenge of Drug-Drug Interactions: A Global Healthcare Crisis

In modern healthcare, few challenges pose as big threats to patient safety such as drug-drug interactions (DDIs). These interactions happen when one medication affects how another medication works when given to the same patient. A drug-drug interaction (DDI) is defined as a pharmacokinetic or pharmacodynamic influence of drugs on each other, which may result undesired effects, in reduced efficacy and effectiveness or increased toxicity [1]. The global scale of this problem is serious: DDIs are estimated to cause 2–5% of hospital admissions in elderly patients, and 1% of hospital admissions in the general population [2].

The scope of the problem goes beyond individual patient cases. Studies show that prevalence of potential DDIs in primary care has been estimated to be high (>60%), although the numbers are lower when clinically significant DDIs are taken into account (3.8–12%) [3]. These interactions can cause various types of patient harm, including liver damage, bleeding, hearing problems, kidney damage, and dangerous blood sugar changes, often with serious consequences for patients and their families.

DDIs are a major global problem because, despite being largely predictable and preventable, they still cause significant clinical and financial harm. They increase hospital stays, treatment costs, and legal expenses, placing heavy strain on healthcare systems—especially those with limited resources. The persistence of DDIs stems mainly from poor information sharing between healthcare providers, particularly when patients see multiple doctors without complete medication records.

The Promise of Connected Healthcare Technology

The modern healthcare landscape is experiencing a digital transformation that offers new solutions to old problems. Healthcare technology integration has emerged as a key strategy for addressing the communication gaps that contribute to medication safety issues. The concept of interoperability, defined as "the ability of two or more systems or components to exchange information and to use the information that has been exchanged" [4], has become central to solving healthcare's fragmented information challenges.

API-driven architectures represent a powerful approach to connecting different healthcare systems and stakeholders. Application Programming Interfaces (APIs) serve as bridges that enable secure data exchange between electronic health records, pharmacy systems, and clinical decision support tools [5]. This technological infrastructure allows healthcare providers to access complete patient information, including medication histories, allergies, and current prescriptions, regardless of where the patient previously received care.

The benefits of connected healthcare systems go beyond simple data sharing. Research shows that healthcare interoperability is "essential for better health service management, public health, quality and safety of care to patients and clinical research" [6]. When healthcare systems can communicate effectively, providers can make more informed decisions, reduce duplicate testing, and most importantly, prevent dangerous medication interactions before they occur.

However, the implementation of connected healthcare technology faces significant challenges. The lack of interoperability in many healthcare systems leads to "redundant, disorganized, disjointed and inadequate" care delivery [6]. This is particularly problematic in developing healthcare systems where technology adoption may be limited and standardization across different healthcare providers is often lacking.

Modern healthcare technology solutions are moving beyond individual applications toward comprehensive ecosystem approaches. Instead of isolated tools, the focus is shifting to platforms that can integrate multiple healthcare functions—from prescription management to patient monitoring—into unified systems that serve all stakeholders: doctors, pharmacists, and patients.

The Algerian Context and the Central Project Goal

Algeria's healthcare system presents a unique set of challenges that exemplify the global DDI management problem while introducing additional complexities specific to developing healthcare infrastructures. Algeria has a public healthcare system, which is accessible and free of charge to all citizens of Algeria, serving a population of approximately 46 million people [7]. However, despite global adoption, digital health in Algeria faces multifarious challenges that inhibit its full-scale development and integration into healthcare services [8].

The fragmentation of Algeria's healthcare system creates particularly dangerous conditions for DDI-related incidents. Unlike integrated healthcare systems where patient information flows seamlessly between providers, Algeria's healthcare landscape is characterized by disconnected prescribing practices, where doctors often lack access to complete patient medication histories. This problem is compounded by the absence of standardized DDI checking systems—a critical gap that leaves healthcare providers without essential safety tools that are considered standard practice in developed healthcare systems.

The communication gap between doctors and pharmacists represents another significant vulnerability in Algeria's medication safety infrastructure. Without integrated digital systems, pharmacists have limited information about prescriptions' clinical context, other patient medications, or contraindications. Most critically, Algeria lacks comprehensive patient medical records that follow individuals across different healthcare encounters, meaning patients receive care from multiple providers without any centralized system to track their complete medication profile.

Despite Algeria's efforts to accelerate its digitization progress, the country faces challenges including an incomplete regulatory framework, a lack of knowledge in using digital service platforms, and providing connection access to remote areas [8]. The economic implications of these gaps are substantial, as preventable medication-related problems place significant financial burden on an already resource-constrained healthcare system.

Our AI-driven prescription safety system addresses these interconnected challenges by providing the first comprehensive DDI management solution specifically designed for Algeria's healthcare context. The system enables real-time drug interaction checking during prescription creation, allows pharmacists to verify prescriptions against complete patient medication

profiles, and empowers patients to maintain comprehensive health records. By leveraging artificial intelligence for DDI prediction and creating secure communication channels between healthcare stakeholders, our system transforms the traditionally fragmented prescription process into a connected, safety-focused ecosystem that demonstrates how modern technology can be successfully implemented in developing healthcare systems.

Structure of the Report

This dissertation is structured to provide a comprehensive analysis of our AI-driven prescription safety system, from theoretical foundations to practical implementation.

Chapter 1: Background

Examines global approaches to DDI management systems and provides detailed analysis of Algeria's healthcare environment and the technological challenges that shape our design requirements.

Chapter 2: System Proposal and Requirements Analysis

Articulates our vision for addressing Algeria's DDI management challenges and establishes the technical and functional requirements, including system architecture overview with core components.

Chapter 3: Design

Provides detailed technical specifications including UML modeling, individual application features, user experience flows, database design, and AI algorithm design for DDI prediction.

Chapter 4: Implementation and Experiments

Demonstrates the practical realization through system technical architecture, development technologies, API presentation, platform demonstration, and AI experiment results validation.

Chapter 5: Conclusion

Synthesizes our contributions to digital health and DDI management, acknowledging limitations while outlining future development directions and broader implications for healthcare digitization in developing systems.

Chapter 1

Background

1.1 Introduction

Drug-drug interactions (DDIs) represent one of the most persistent and costly challenges in healthcare, contributing to approximately 15-20% of all adverse drug events and resulting in billions of dollars in preventable healthcare costs annually [9]. Modern pharmacotherapy increasingly involves multiple medications simultaneously, transforming DDI management from a clinical consideration into a critical patient safety imperative. Algeria's healthcare landscape exemplifies challenges faced by developing nations in implementing DDI management systems, with limited integration between prescribing physicians, dispensing pharmacists, and patient care coordination [10].

This chapter analyses existing DDI management approaches through a global taxonomy of current systems, examines challenges and opportunities within the Algerian healthcare context, and establishes the foundation for an ecosystem approach. The analysis examines four DDI management models, evaluates their effectiveness and limitations, and explores Algeria's healthcare and technology landscape to identify improvement opportunities.

1.2 A Global Taxonomy of DDI Management Systems

1.2.1 Model 1: The Integrated Clinical Decision Support System (CDSS)

Core characteristics and DDI management approach

Clinical Decision Support Systems represent the most sophisticated approach to DDI management within healthcare institutions. These systems are embedded within electronic health record (EHR) platforms, providing real-time alerts and recommendations during prescribing [11]. The core architecture relies on patient data integration, including current medications, medical history, laboratory results, and demographics, to provide contextually relevant interaction alerts [12].

The DDI management approach operates through rule-based algorithms that monitor medication orders against interaction databases. When potential interactions are detected, the system generates alerts with varying severity levels, categorized as contraindicated, major, moderate, or minor interactions [13]. Implementations incorporate clinical context, such as dosage, timing, and patient-specific factors like renal function or age, to reduce alert fatigue while maintaining safety standards.

Representative systems and their DDI handling mechanisms

Epic's MyChart and EpicCare systems exemplify leading CDSS implementations, incorporating DDI checking through medication management modules. The Epic platform utilizes proprietary and licensed drug databases, including First Databank and Medi-Span, to provide multi-layered interaction screening [14]. DDI alerts are contextualized based on patient-specific parameters and can be customized by healthcare institutions.

Cerner's PowerChart platform features DDI management through its Medication Reconciliation and Clinical Decision Support modules. Cerner's approach emphasizes workflow integration, presenting DDI alerts within the natural prescribing workflow without disrupting clinical efficiency [15]. The system supports both passive monitoring and active intervention, allowing clinicians to override alerts with documented justification while maintaining audit trails.

Clinical integration benefits and implementation challenges

The primary advantage of CDSS DDI management lies in integration with clinical workflows, providing contextual alerts at optimal decision-making moments. Studies demonstrate that well-implemented CDSS can reduce DDI-related adverse events by 20-50% while improving medication safety outcomes 20-50% while improving overall medication safety outcomes [16]. Patient data access enables more accurate risk assessment and personalized recommendations compared to standalone systems.

However, implementation challenges are substantial. Alert fatigue remains persistent, with clinicians overriding 80-90% of DDI alerts, often due to irrelevant or low-severity warnings [17]. High implementation and maintenance costs create barriers for resource-constrained healthcare systems [18]. Additionally, system customization complexity and staff training requirements can extend implementation timelines and increase adoption resistance among healthcare providers.

1.2.2 Model 2: The Standalone DDI Database/Checker

Functionality and scope in DDI detection

Standalone DDI database and checker systems represent the most widely accessible approach to drug interaction screening, operating as independent platforms focused exclusively on medication safety analysis. These systems maintain drug interaction databases derived from clinical literature, regulatory submissions, and post-market surveillance data [19]. The core functionality centers on batch processing of medication lists, where users input current medications and receive interaction reports with clinical significance assessments.

DDI detection scope encompasses pharmacokinetic and pharmacodynamic interactions, contraindications, therapeutic duplications, and allergy cross-reactions. Platforms incorporate severity classification systems based on clinical significance, onset timing, and documentation quality [20], extending beyond detection to provide mechanism explanations and management recommendations.

Major platforms and their methodologies

VIDAL, one of Europe's most widely used pharmaceutical reference platforms, provides

DDI checking through mobile and web applications. The platform utilizes a database tailored to European and French pharmaceutical markets [21]. VIDAL's methodology emphasizes clinical practicality through risk-stratified alerts with mechanism explanations and evidence-based management recommendations. The system has gained adoption among Algerian healthcare professionals due to its French-language interface and inclusion of medications commonly available in the Algerian pharmaceutical market

DrugBank represents an open-access pharmaceutical knowledge base providing DDI information alongside drug characterization data. The platform employs interaction documentation, integrating molecular-level drug information with clinical evidence from peer-reviewed literature [22]. DrugBank's methodology focuses on mechanism-based interaction prediction, utilizing molecular structure analysis and pathway mapping to identify potential interactions beyond those documented in clinical studies.

Limitations in workflow integration and real-time decision support

Despite databases and analysis capabilities, standalone DDI checkers face workflow integration limitations. The primary constraint lies in their disconnection from patient care processes, requiring manual medication list entry and lacking access to real-time patient data [23]. This creates workflow disruptions where clinicians must actively seek interaction checking rather than receiving alerts at natural decision points.

The absence of real-time decision support represents another limitation, as standalone systems cannot provide alerts during prescribing or monitor for newly identified interactions as regimens evolve. Studies show that manual consultation leads to inconsistent usage patterns, with interaction checking occurring in less than 30% of appropriate clinical scenarios [24]. The lack of integration with electronic prescribing systems prevents automatic updating of interaction assessments and limits incorporation of patient-specific factors such as genetic variations or organ function status [25].

1.2.3 Model 3: Advanced AI and Predictive Analytics Platforms

Machine learning approaches to DDI prediction

AI and predictive analytics platforms represent the evolution of DDI management systems, leveraging machine learning methodologies to predict drug interactions beyond traditional rule-

based approaches. The approach involves training models on pharmaceutical and clinical datasets to identify interaction patterns not apparent through conventional analysis methods [26]. These systems employ supervised learning approaches, where models learn from known drug interaction pairs, and unsupervised techniques that discover hidden patterns in drug behavior and molecular characteristics.

Unlike static database systems, AI-driven platforms can generalize from existing interaction knowledge to predict potential interactions for novel drug combinations, including newly approved medications with limited clinical interaction data [27]. This predictive capability is valuable in identifying rare or previously unrecognized interactions in polypharmacy scenarios.

Current AI methodologies and algorithms in use

Natural language processing (NLP) techniques extract DDI information from unstructured clinical literature, electronic health records, and adverse event reports. NLP models, including transformer-based architectures like BERT, identify interaction mentions, extract severity classifications, and synthesize evidence from multiple textual sources [28]. These systems process biomedical literature to continuously update interaction databases with newly published findings.

Machine learning algorithms including support vector machines (SVM), Naive Bayes, logistic regression, XGBoost, LightGBM, convolutional neural networks (CNNs), and LSTM networks model drug interaction patterns using various feature representations [29]. Deep learning approaches, particularly neural networks, capture non-linear relationships between drug characteristics and interaction outcomes. Ensemble methods like XGBoost have shown promising results in DDI prediction tasks [30].

Content-based feature approaches utilize intrinsic drug properties as predictive features. These systems integrate molecular descriptors, pharmacological properties, chemical fingerprints, drug target information, and metabolic pathway data to characterize drugs and predict their interaction potential [31]. BContent-based approaches can predict interactions for new drug combinations even when limited clinical interaction data is available [32].

Research advances and technological capabilities

Recent research advances have focused on multi-modal learning approaches that integrate

diverse data sources including genomics, proteomics, clinical outcomes, and real-world evidence to enhance DDI prediction accuracy [33]. Feature engineering techniques, including dimensionality reduction and feature selection methods, help identify the most predictive drug characteristics while reducing computational complexity.

Explainable AI (XAI) methodologies are being integrated into DDI prediction systems to provide interpretable insights into interaction mechanisms and risk factors. Attention-based models help clinicians understand which molecular features or drug combinations contribute most significantly to predicted interactions [34].

Limitations and accuracy challenges

AI-based DDI prediction systems show promise, but several considerations affect their clinical implementation. Data quality and completeness influence model performance, as interaction databases require continuous updating with emerging clinical evidence [35]. Prediction models must balance sensitivity and specificity to provide clinically useful recommendations while minimizing false alerts.

The evolving nature of pharmaceutical knowledge necessitates ongoing model validation and updates to incorporate new interaction discoveries and changing clinical understanding [36]. These considerations highlight the importance of developing validation frameworks and maintaining flexibility in AI system design.

1.2.4 Model 4: Patient-Centered mHealth Applications

Consumer-facing DDI management features

Patient-centered mobile health applications shift DDI management by enabling patients to participate in their medication safety through mobile platforms. These applications provide DDI checking capabilities, allowing patients to input their medications and receive interaction alerts and safety recommendations [37]. The approach includes interfaces that present pharmaceutical information using visual indicators, severity ratings, and plain-language explanations.

Health DDI applications incorporate medication databases that include prescription drugs, over-the-counter medications, dietary supplements, herbal products, and foods. Applications use barcode scanning and drug recognition features to simplify medication entry [38]. Many

platforms integrate with pharmacy systems and electronic health records to populate medication lists automatically.

Patient engagement and medication safety tools

Patient-centered mHealth applications incorporate medication management features including medication reminders, dosage tracking, refill notifications, and side effect monitoring [39]. DDI checking integrated within medication management workflows ensures that interaction monitoring becomes part of patients' medication routines.

Educational components provide information about interaction mechanisms, symptoms to monitor, and actions when interactions are identified. Applications include risk assessments considering patient factors such as age, medical conditions, and medication history [40]. Platforms incorporate communication features enabling patients to share interaction alerts and medication lists with healthcare providers.

Clinical accuracy and professional oversight concerns

Patient-centered DDI applications present both opportunities and challenges for medication safety. These applications provide safety nets by enabling patients to identify interactions that may be overlooked in clinical settings, but concerns exist regarding clinical validation of interaction databases and patient-initiated medication adjustments [41].

Professional oversight considerations are important because patients may misinterpret interaction alerts or make medication changes without consulting healthcare providers. Patient-centered DDI applications address these concerns by emphasizing professional consultation, providing guidance on when to contact healthcare providers, and avoiding recommendations that could encourage discontinuing prescribed medications without medical supervision [42]. Successful platforms establish boundaries between patient empowerment and professional medical decision-making, using technology to enhance rather than replace the patient-provider relationship [43].

1.2.5 Comparative Analysis and Gaps

Comparison across the four models reveals strengths and limitations. CDSS platforms show 20-50% reductions in DDI-related adverse events [44]. but alert fatigue compromises effec-

tiveness with override rates reaching 80-90%. Standalone DDI checkers provide databases but show limited impact due to workflow disconnection, with utilization rates below 30% [45]. AI platforms achieve prediction accuracies exceeding 90% in studies, but real-world validation remains limited [46].

Integration challenges exist across all models. CDSS platforms require integration with hospital systems, creating implementation costs that exceed institutional capabilities in resource-constrained environments [47]. Standalone systems face workflow disruptions. AI platforms encounter challenges with data quality, model validation, and updates. The lack of interfaces creates inconsistent interaction checking across care points [48].

Each model addresses DDI management aspects while leaving gaps. CDSS platforms excel in clinical integration but suffer from costs and alert fatigue. Standalone systems provide databases but lack workflow integration. AI platforms offer prediction capabilities but face validation challenges. Patient-centered mHealth applications enhance engagement but raise accuracy concerns [49].No single model addresses medication safety across the management process [50]. This fragmentation highlights the need for approaches combining model strengths.

1.3 The Algerian Reality: Healthcare, Technology, and System Integration Challenges

1.3.1 Healthcare System Structure and DDI Management Practices

Algeria's healthcare system operates through public and private sectors, with public services provided through polyclinics, hospitals, and medical centers across 58 provinces [51]. Current workflows are fragmented with limited integration between prescribing physicians and dispensing pharmacists. Physicians provide handwritten prescriptions that patients carry to pharmacies, where medications are dispensed based on prescription legibility and availability rather than interaction checking [52]. Without electronic prescribing systems, medication histories and adverse reactions are rarely accessible

DDI detection relies on individual practitioner knowledge rather than screening. While healthcare professionals access resources like VIDAL through mobile applications, utilization remains inconsistent and depends on individual initiative rather than institutional protocols

[53]. Communication gaps exist between healthcare stakeholders, as integrated systems between hospitals, primary care centers, and pharmacies are lacking. Medication changes and interaction concerns are rarely communicated across care transitions [54]. This creates opportunities for DDIs to emerge undetected, particularly in patients receiving care from multiple providers.

1.3.2 Technology Infrastructure and Digital Health Landscape

Algeria's digital health landscape reflects investments in telecommunications infrastructure. Internet penetration has reached 60% of the population, while mobile phone adoption exceeds 85% [55]. Digital health initiatives include pilot projects for electronic health records in major hospitals and telemedicine for remote areas. The Ministry of Health has launched digitization programs for healthcare data management, though implementation varies across regions [56]. Most providers still rely on paper-based systems.

Smartphone adoption has grown, with over 70% of mobile users accessing internet through mobile devices [57]. This creates opportunities for mHealth applications, while 4G networks provide infrastructure for real-time data exchange. The regulatory environment is evolving to accommodate digital health innovations while maintaining safety protections. Recent legislation on data protection and medical devices provides a framework for health technology implementation, though guidelines for mobile health applications and AI systems are under development [58]. The regulatory approach emphasizes patient safety while encouraging innovation.

1.4 Justification for an Integrated Ecosystem Approach

1.4.1 Limitations of Current Models in the Algerian Context

Implementation of existing DDI management models in Algeria faces constraints that limit effectiveness and sustainability. CDSS systems demand capital investments in electronic health record platforms, network infrastructure, and technical support that exceed the financial capacity of many Algerian healthcare institutions [59]. Resource allocation priorities emphasizing basic medical services often preclude investments required for clinical decision support implementation.

Standalone DDI databases and mobile applications, such as VIDAL, while more accessible than integrated CDSS systems, present their own implementation challenges. Despite widespread VIDAL adoption among Algerian healthcare professionals due to its French-language interface and inclusion of medications commonly available in the Algerian market [60], these platforms suffer from workflow integration issues that limit clinical effectiveness. Standalone systems require manual medication list entry and lack access to real-time patient data, creating workflow disruptions [61].

Algeria's fragmented healthcare communication systems compound these limitations, as standalone platforms cannot bridge communication gaps between prescribing physicians and dispensing pharmacists [62]. Healthcare professionals must actively seek interaction checking rather than receiving alerts at decision points. This manual consultation approach occurs in less than 30% of clinical scenarios, leaving many potential interactions undetected [63].

1.4.2 The Ecosystem Advantage

Multi-stakeholder integration recognizes that medication safety is a collaborative process involving physicians, pharmacists, and patients throughout the medication management continuum. An ecosystem approach addresses communication gaps in Algeria's healthcare system by providing shared platforms for medication information exchange, interaction alerts, and safety monitoring [64]. This ensures DDI detection and management occur at multiple points in the medication use process, creating safety checks while distributing responsibility across participants.

AI-driven prediction enhanced by data sharing represents an ecosystem advantage, as machine learning algorithms perform optimally when provided with diverse datasets reflecting real-world medication use patterns. By integrating data from prescribing decisions, dispensing records, patient adherence monitoring, and adverse event reporting, an ecosystem approach creates datasets enabling accurate DDI prediction and risk assessment [65]. In Algeria, this addresses current fragmentation of medication information across healthcare providers, capturing medication histories from multiple sources and providing a view of patient medication exposure currently unavailable [66].

Scalability and sustainability advantages stem from distributed architecture and shared re-

source utilization. Rather than requiring each healthcare institution to implement independent DDI management systems, the ecosystem approach leverages cloud-based infrastructure and shared databases that distribute costs across multiple users while providing functionality [67]. This model is advantageous for Algeria's healthcare environment, where individual institutions may lack technical or financial resources for independent system implementation [68].

1.5 Conclusion

This chapter explored global drug-drug interaction (DDI) management systems across four distinct models: integrated Clinical Decision Support Systems (CDSS), standalone interaction databases, AI-driven predictive platforms, and patient-centered mHealth applications. Each model exhibits critical limitations—whether in integration, real-time usability, predictive accuracy, or professional oversight. No single approach fully addresses DDI prevention complexities across the entire medication lifecycle.

The chapter proposed the ecosystem approach as a contextually grounded alternative. By integrating multiple stakeholders and leveraging AI within a data-rich environment, this approach offers enhanced predictive accuracy, improved coordination, and scalable infrastructure tailored to Algeria's healthcare realities. This foundation sets the stage for designing a robust, AI-driven DDI management system capable of bridging existing gaps and aligning with the country's digital health ambitions.

Chapter 2

System proposal and requirement analysis

2.1 Introduction

Here, we lay out the groundwork for an AI-powered healthcare platform focused on keeping patients safe in Algeria by preventing harmful drug interactions. Well cover the vision and mission behind the project, dive into the functional and non-functional requirements for patients, doctors, and pharmacists, and sketch out the systems architecture, highlighting its main components: the pharmacy and doctor desktop apps, the patient mobile app, and the AI engine driving drug interaction predictions.

2.2 Vision and Mission

Our vision is to revolutionize patient safety in Algeria's healthcare system through an integrated, AI-driven ecosystem that connects patients, healthcare providers, and pharmacists to prevent drug-drug interactions and enhance clinical outcomes. Our mission is to design and implement a comprehensive healthcare platform leveraging advanced artificial intelligence and API-driven architectures to enhance patient safety through AI-powered drug interaction detection, improve system interoperability via secure standardized APIs, empower stakeholders with intuitive role-specific interfaces, support scalability and accessibility across urban and rural regions, and ensure compliance with Algerian data protection laws and international health standards, ultimately creating a transformative digital health model for Algeria and the broader North African region.

2.3 Requirements Specification

The goal of this project is to develop an intelligent digital platform that facilitates the detection of potential drug-drug interactions (DDIs) using AI, while improving coordination between patients, doctors, and pharmacists. This platform consists of a mobile application for patients and a desktop interface for healthcare professionals. The system aims to be scalable, secure, and aligned with medical data privacy standards. We distinguish between two types of requirements:

- Functional Requirements: Describe what the system should do (features and capabilities).
- Non-Functional Requirements: Describe how the system should behave (usability, performance, security, etc.).

2.3.1 Functional Requirements

1a. For Patients (Mobile Application) The platform must allow patients to:

- **User Registration and Authentication**: Patients must be able to securely register and authenticate using their email, phone number, and password. The system verifies the uniqueness of contact information and stores credentials safely.
- **Medication Interaction Checker:**Patients can input one or multiple medications to check for potential interactions. The AI-powered engine analyzes drug combinations and provides detailed risk levels (Major, Moderate, Minor), with appropriate explanations and precautionary advice.
- **View and Manage Prescriptions:** Patients can view their current and historical prescriptions, including drug names, dosages, frequencies, and usage instructions.
- **Medical Reminder System:** Patients can set reminders for medication intake and mark them as completed to maintain adherence.
- **Consent-Based Data Sharing:** Patients receive and respond to access requests

from doctors and pharmacists. Only after approval can these users view sensitive information, ensuring control over medical data and patient privacy.

- **Profile and Medical Info Management:** Patients can update their profile, medical conditions, allergies, and notes from the app interface.

1b. For Doctors (Desktop App) The platform must allow doctors to:

- **Secure Login and Role-Based Access:**Doctors must log in securely and access a dedicated dashboard tailored to their medical practice.
- **Patient Management:**Doctors can add patients using insurance numbers or QR codes, search and manage their medical information, and view their prescription history.
- **Prescription Creation and Interaction Alerts:**Doctors can create new prescriptions for patients. Before confirmation, the system checks for possible interactions using the AI model. If a conflict is detected, the doctor is alerted and may override it if justified.
- **Medication Search:**Doctors can search for medications from a centralized database when writing a prescription. Medication details such as scientific name, dosage form, and instructions are displayed for reference.
- **Prescription Modification and Validation:**Doctors can edit or validate prescriptions in real-time, and each action is tracked for audit purposes.

1c. For Pharmacists (Desktop Application) The platform must allow pharmacists to:

- **Authentication and Account Access:**Pharmacists must securely log in using their credentials and access features based on their role.
- **Manage and Search Patients:**Pharmacists can register new patients or search ex-

isting ones using insurance numbers. They can only view profiles once access is granted by the patient.

- **Prescription Verification and Validation:**Pharmacists review doctor-issued prescriptions and validate them before dispensing. The system ensures that no medication is delivered without pharmacist approval.
- **Check OTC Medication Interactions:**Pharmacists can enter non-prescribed drugs a patient wants to purchase. The system checks for interactions using the AI model before proceeding with the sale.
- **Inventory Management:**Pharmacists can view, add, update, and remove medication products from stock. The platform also supports product search and sends low-stock alerts.
- **Doctor Profile Access:**Pharmacists can view or update their professional profile and settings.

2.3.2 Non-Functional Requirements

The application must also meet the following non-functional requirements:

- **Security and Privacy:**The system must ensure that medical data is securely stored and accessed only by authorized users. Patient data sharing is only allowed after explicit consent, and all actions are logged for traceability.
- **Performance:** The platform must respond quickly to user actions, especially when checking for drug interactions. Delays should be minimal to support smooth medical workflows.
- **Scalability** The architecture must support an increasing number of users and data without performance loss. It should also be ready for future upgrades and added features.
- **Reliability:** The platform must maintain high availability and minimize downtime. Essential features must remain operational, especially during emergencies.
- **Usability:** The interface should be simple and accessible to both patients and health-

care professionals. Clear navigation and multilingual support (Arabic and French) are essential.

- **Responsiveness:** The mobile app must be fully responsive, adapting to different screen sizes and devices without issues.
- **Legal Compliance:** The platform must follow Algerian laws on data protection and align with health data confidentiality standards.

2.4 System Architecture Overview

2.4.1 Introduction

The proposed system architecture represents a comprehensive, integrated healthcare ecosystem designed to revolutionize medication safety through intelligent drug-drug interaction (DDI) prediction and management. At its core, the system orchestrates seamless communication between healthcare providers, pharmacists, and patients while leveraging advanced artificial intelligence to predict and prevent potentially harmful drug interactions.

The architecture operates on the principle of collaborative healthcare management, where each stakeholder has access to specialized tools tailored to their specific roles and responsibilities. Doctors utilize sophisticated prescribing interfaces that provide real-time interaction checking, pharmacists employ comprehensive validation systems for prescription processing, and patients benefit from personalized medication management tools that keep them informed and engaged in their treatment process.

The system's intelligence is powered by a centralized AI model that continuously analyzes medication combinations, patient profiles, and clinical data to provide accurate DDI predictions. This creates a dynamic safety net that operates across all points of medication management—from initial prescription to final dispensing and ongoing patient monitoring.

2.4.2 Core Components

2a. Pharmacy Desktop Application The pharmacy desktop application serves as the primary interface for pharmacists to manage prescriptions, validate drug interactions, and coordinate patient care. This component provides comprehensive tools for prescription processing while ensuring medication safety through intelligent DDI screening.

Key Functionalities:

- Prescription processing and validation with automated safety checks
- Real-time DDI screening and alerts powered by the AI model
- Patient medication history management
- Inventory management and drug information database
- Comprehensive reporting and analytics dashboard for clinical decision support

The application receives electronic prescriptions and immediately processes them through the AI model to identify potential interactions with the patient's existing medications. When DDIs are detected, pharmacists receive detailed alerts with severity assessments, clinical recommendations, and suggested alternatives. The system maintains complete patient profiles that extend beyond prescription history to include documented allergies, previous adverse reactions, and patient-reported medications from the mobile application.

2b. Doctor Desktop Application The doctor desktop application empowers healthcare providers with intelligent prescribing capabilities and comprehensive patient management tools. This component facilitates evidence-based prescribing decisions by integrating DDI checking directly into the clinical workflow.

Key Functionalities:

- Electronic prescribing with embedded DDI checking through real-time AI model

integration

- Patient medical history and medication review with comprehensive interaction analysis
- Clinical decision support system integration providing detailed interaction mechanisms and alternatives
- Drug interaction alerts and alternative medication suggestions ranked by therapeutic equivalence
- Patient monitoring and follow-up management with automated safety protocols
- Integration with Electronic Health Record (EHR) systems for seamless workflow adoption

The application continuously evaluates prescription combinations against the patient's complete medication profile as physicians make prescribing decisions. When potential DDIs are identified, the system provides detailed clinical context including interaction mechanisms, severity assessments, and management recommendations.

2c. Patient Mobile Application The patient mobile application provides patients with intelligent medication management tools. This component empowers patients to become active participants in their medication safety while providing healthcare teams with valuable adherence and safety data.

Key Functionalities:

- Personal medication tracking and reminder system with intelligent scheduling
- Drug interaction awareness tailored to individual medication regimens
- Medication adherence monitoring with pattern analysis and intervention suggestions
- Health data logging and medical history

The application maintains a comprehensive medication inventory including all prescrip-

tions, automatically updating when new ones are filled. The patients can check medications and the AI model immediately assesses potential interactions and provides clear, understandable safety information.

2d. AI Model for DDI Prediction The AI model represents the intelligent core of the system, providing advanced drug-drug interaction prediction capabilities that power all safety assessments across the platform. This component incorporates sophisticated machine learning algorithms to analyze medication combinations and generate personalized interaction predictions.

Key Functionalities:

- Machine learning-based DDI prediction using comprehensive pharmaceutical and clinical datasets
- Risk assessment and severity classification with confidence scoring for clinical decision support
- Integration with pharmaceutical databases and research literature for current interaction knowledge
- Real-time processing and response generation to support immediate clinical decision-making

The AI model processes multiple data streams simultaneously. The system goes beyond documented interactions by analyzing molecular structures and metabolic pathways to predict potential interactions between drug combinations with limited clinical study data. The model can continuously refine predictions and adapt to emerging interaction patterns.

2.4.3 System Integration and Unified Operation

3a. Comprehensive Data Flow and Inter-Component Communication The system operates as a unified ecosystem where information flows seamlessly between all components, creating a comprehensive safety network that spans the entire medication management

process. This integration ensures that critical safety information is available to all stakeholders at precisely the right moment in their respective workflows.

Prescription Initiation and Safety Screening: The process begins when a physician starts prescribing new medications, each potential addition is continuously evaluated against the patient's existing regimen. The AI model processes these combinations in real-time, considering drug-drug interactions. When the physician finalizes a prescription, the system generates a comprehensive safety profile that accompanies the prescription to the pharmacy. This profile includes interaction assessments.

Pharmacy Validation and Dispensing Process: Upon receiving the electronic prescription, the pharmacy desktop application immediately cross-references the prescribed medication against the most current patient medication profile. The AI model performs a fresh analysis incorporating any new medications the patient may have started. If new interactions are identified or if the interaction profile has changed since prescription, the pharmacy system alerts the pharmacist. This creates a collaborative consultation environment where both healthcare providers can resolve safety concerns before medication dispensing occurs. The pharmacy application also considers practical factors such as drug availability and therapeutic alternatives when interaction issues arise.

Patient Engagement and Ongoing Monitoring: Once a prescription is dispensed, the patient's mobile application automatically updates with the new medication information. The mobile application provides patients with personalized education about their new medication. Additionally, patients can search for medications and check for interactions when purchasing supplements over the counter, enabling them to make informed decisions before adding new medications to their regimen.

Benefits of the Integrated Architecture This comprehensive system architecture creates a transformative approach to medication safety management that extends far beyond traditional interaction checking systems. The integrated design produces several critical advantages:

Enhanced Patient Safety Through Multi-Point Verification: The system creates multiple safety checkpoints throughout the medication management process, from initial prescribing through ongoing patient monitoring. This redundant safety approach sig-

nificantly reduces the likelihood that dangerous drug interactions will go undetected, as each component serves as both a primary safety tool and a backup verification system for the others.

Patient Empowerment and Engagement: By providing patients with comprehensive, understandable information about their medications and potential interactions, the system transforms patients from passive recipients of care into active participants in their medication safety. This engagement improves adherence, reduces adverse events, and enhances overall treatment effectiveness.

Seamless Clinical Workflow Integration: The architecture recognizes that successful implementation requires minimal disruption to existing healthcare practices. Each component is designed to enhance rather than replace current workflows, ensuring that safety improvements do not come at the cost of clinical efficiency or provider satisfaction.

This integrated approach represents a fundamental shift from reactive interaction management to proactive, comprehensive medication safety that spans the entire healthcare ecosystem while maintaining focus on practical implementation and real-world effectiveness.

2.5 Conclusion

We've mapped out the foundation for a game-changing healthcare platform aimed at boosting medication safety across Algeria. By setting a clear vision and mission, spelling out detailed requirements for all users, and outlining a cohesive system architecture with tailored components for pharmacies, doctors, patients, and AI-driven interaction checks, we've created a solid starting point. This framework paves the way for a system that encourages collaboration, prioritizes patient safety through smart drug interaction management, and ensures scalability, security, and alignment with healthcare standards, readying us for the next steps in development and rollout.

Chapter 3

Design

3.1 Introduction

The design phase translates the proposed system architecture into practical models that define how each component functions and interacts. It establishes a coherent framework in which doctors and pharmacists operate through dedicated desktop applications, patients manage their health via a mobile interface, and all stakeholders are supported by an AI engine for drug–drug interaction prediction. This stage ensures that the system meets user needs while maintaining integration, security, and consistency across the healthcare process.

This chapter introduces the design of the system through its main elements. It outlines the features of each application, presents user experience flows, and employs UML diagrams to formalize system behavior and structure. The chapter also covers dataset design and the selection of AI algorithms for interaction prediction, providing a comprehensive blueprint that prepares the system for implementation.

3.2 Individual Application Features

This section describes the specific features of each part of our AI-driven prescription safety system. Our system has two main applications: desktop app for doctors and pharmacists, and a mobile app for patients. Each app has features designed for its specific users while working together to prevent dangerous drug interactions.

3.2.1 Desktop Application

The desktop application serves both healthcare providers - doctors and pharmacists - with shared core functionalities and role-specific features. Both user types use the same interface design and security protocols while accessing features appropriate to their professional roles.

Patient Search and Access Management: Both doctors and pharmacists start by searching for patients using their insurance number. After finding the patient, they send an access request to the patient's phone. The patient gets a notification inside their mobile app and can approve or reject the request. This system makes sure patients control who can see their medical information while letting healthcare providers deliver proper care when needed. The pharmacy side includes additional security features to verify patient identity during medication pickup and ensure prescription authenticity to prevent fraud.

Patient Information Viewing: When a patient approves the healthcare provider's request, both doctors and pharmacists can see important patient information including full name, height, weight, date of birth, blood type, allergies, medical conditions, and gender. This information helps doctors choose the right medications and avoid prescribing drugs that could cause allergic reactions or interact badly with the patient's health conditions. For pharmacists, this same information enables appropriate medication counseling and helps identify potential issues during dispensing.

Prescription Creation and Management: Both doctors and pharmacists can add multiple medications to one prescription and include detailed instructions like how much to take, how often, and whether to take it with food or on an empty stomach. The system has a search feature to find medications quickly and keeps a record of all prescriptions created for future reference. Doctors primarily use this for creating new prescriptions for patients, while pharmacists can create prescriptions when authorized and can view all prescriptions waiting to be filled with clear status indicators (new, partially filled, or completed).

Integrated DDI Checking System: When either doctors or pharmacists try to save a prescription, our AI system checks for dangerous drug interactions using the same algorithms and safety standards. If it finds any problems, it shows a warning with details on how serious the interaction is, what could happen to the patient, and what the healthcare provider should do. The user then has the option of picking a different medication than the one causing the dan-

gerous interaction or continuing with the prescription process. For pharmacists, this serves as a secondary safety check that complements the initial screening performed during prescription creation, including analysis of over-the-counter medications and supplements.

3.2.2 Mobile Application

The mobile application lets patients control their medical information and track their medications.

Access Control and Privacy Management: Patients use the mobile app to control who can see their medical information. When doctors or pharmacists request access, patients get notifications inside the app and can approve or deny the request. The app keeps a log of who has requested access and when, so patients know exactly who has seen their information and can trust the system.

Personal Health Information Management: Patients can view and update their personal information like allergies, medical conditions, and basic details through the mobile app. When patients make changes, the updates show up immediately in the doctor and pharmacy apps, so healthcare providers always have the most current information when making treatment decisions.

Prescription and Medication Viewing: Patients can see all their current and past prescriptions through the mobile app. The app shows medication information including how much to take, when to take it, and any important notes. This helps patients keep track of their medications and understand their treatment.

3.2.3 Cross-Application Integration Features

Unified System Integration: The desktop and mobile apps work together using the same patient information, so when something changes in one app, it updates for all other users immediately. The AI system that checks for drug interactions works the same way everywhere, using the same safety standards whether a doctor or pharmacist creates the prescription. The system keeps detailed records of everything that happens for accountability and tracks all information in real-time to prevent dangerous gaps in patient care.

3.3 User Experience Flows

The following flowcharts illustrate the operational workflows for each of the three main user interfaces within the proposed DDI prediction system. These diagrams demonstrate how different stakeholders—patients, pharmacists, and doctors—interact with their respective applications and how the system facilitates medication safety through structured decision-making processes. Each flowchart maps the user journey from authentication through core functionalities, highlighting the integration of AI-powered DDI checking at critical decision points. These workflows represent the practical implementation of the system architecture, showing how theoretical safety mechanisms translate into real-world user experiences and clinical workflows.

3.3.1 Patient Mobile Application Workflow

This flowchart depicts the patient-centered workflow within the mobile application, beginning with user authentication and branching into the application's core functionalities. The workflow demonstrates how patients can access various features including profile management, notification handling, medication searching, interaction checking, and medication management. A key component of this workflow is the medication reminder system, which includes a decision point for reminder activation and subsequent notification delivery. The flowchart emphasizes patient empowerment through self-service medication management tools and proactive interaction checking capabilities.



Figure 3.1: Patient Mobile Application Workflow

3.3.2 Pharmacy Desktop Application Workflow

This flowchart illustrates the pharmacist's operational workflow within the desktop application, starting with professional authentication and expanding into comprehensive pharmacy management functions. The workflow encompasses multiple parallel processes including dashboard analytics, medication search and interaction checking, client management, inventory control, and profile management. The central process focuses on prescription dispensing, which includes a critical decision point for interaction detection. When interactions are identified, the system generates alerts; when no interactions are found, prescriptions proceed to dispensing. This workflow demonstrates how the system integrates safety checks into routine pharmacy operations while maintaining operational efficiency.



Figure 3.2: Pharmacy Desktop Application Workflow

3.3.3 Doctor Desktop Application Workflow

This flowchart represents the physician's workflow within the desktop application, beginning with medical professional authentication and branching into clinical management functions. The workflow includes dashboard access, medication search and interaction analysis, patient management, appointment scheduling, and profile management. The core prescribing process incorporates a critical safety checkpoint where the AI model evaluates potential drug interactions. Based on this analysis, the system either saves the prescription (when no interactions are detected) or generates interaction alerts (when potential DDIs are identified). This workflow demonstrates how clinical decision support is seamlessly integrated into the prescribing process, enhancing medication safety without disrupting established clinical practices.



Figure 3.3: Doctor Desktop Application Workflow

3.4 UML diagrams

UML diagrams serve as an effective tool for understanding the structure, functionalities,and behavior of the system. They help visualize how different users—such as patients, doctors, and pharmacists—interact with the platform, as well as how internal components are organized and communicate with each other. This section includes three main types of diagrams

Use Case Diagrams: To show how users such as patients, doctors, and pharmacists interact with the system and what functionalities are available to each. **Class Diagram:** To describe the static structure of the system, including entities, their attributes, and relationships. **Sequence Diagrams:** To demonstrate the flow of interactions between different system components in specific scenarios, such as adding a prescription or checking for drug interactions.

These diagrams form a key reference for the implementation phase and help ensure shared understanding among development team members and stakeholders.

3.4.1 Use Case Diagrams

Patient use case and Detailed Specification The figure 3.4 illustrates the use cases of the Patient.



Figure 3.4: the use case of Patient.

Actor	Functionalities
Patient	• **Authentication:** Login to the mobile application securely. • **Medication Management:** View current prescriptions and medication details. • **Interaction Checking:** Use AI-powered system to check for harmful drug interactions. • **Authorization of Access Requests:** Approve or deny doctor/pharmacist access to medical profile. • **Medication Reminders:** View medication reminders and mark them as completed. • **Profile Settings:** View and edit personal profile data.

Table 3.1: Detailed Description of Patient use case

Doctor use case and Detailed Specification

The figure 3.5 illustrates the use cases of the Doctor.



Figure 3.5: the use case of Doctor.

Actor	Functionalities
Docteur	• **Authentication:** Login to the platform using personal credentials. • **Manage Patients:** Add patients using insurance number or QR code, search, or delete patients. • **View Patient Profile:** Access medical history and previous prescriptions for each patient. • **Prescription Writing:** Assign medications with automatic interaction checking using the AI engine. • **Schedule Appointments:** Create, edit, or view appointment schedules. • **Check Medication Interactions:** Run real-time interaction checks between medications. • **Monitor Dashboard & Statistics:** Access alerts and performance analytics in a medical-oriented dashboard. • **Doctor Profile Settings:** View and edit personal profile information.

Table 3.2: Detailed Description of Doctor use case

Pharmacists use case and Detailed Specification

The figure 3.6illustrates the use cases of the Pharmacists.



Figure 3.6: the use case of Pharmacists.

Actor	Functionalities
Pharmacist	• **Authentication:** Secure login to the pharmacist interface. • **Manage Patients:** Add new patients via QR or insurance number, or search existing profiles. • **View Patient Profile:** Access prescriptions after patient approval. • **Prescription Validation:** Approve prescriptions after verifying drug safety with the AI engine. • **OTC Interaction Checking:** Check interactions for over-the-counter medications without prescriptions. • **Inventory Control:** Add, update, delete, and search stock in the pharmacy. • **Monitor Dashboard & Statistics:** Track pharmacy activity, interactions, and stock alerts. • **Pharmacist Profile Settings:** Manage and update profile information.

Table 3.3: Detailed Description of Pharmacists use case

3.4.2 Class Diagrams

The figure 3.7 our class diagram illustrates the data model of the system. Specifically, our class diagram is a conceptual data model (CDM) that represents the data required for the proper implementation of the various features to be offered by our website.



Figure 3.7: our class diagram.

Class Diagram Overview

The class diagram outlines the main components of the drug interaction detection system and how they interact. It models the key entities, their attributes, and the relationships between them.

The **Patient, Doctor,** and **Pharmacist** classes represent the main user roles, each with personal and professional data, along with actions such as registration, login, and profile management. Patients can update their medical information, while doctors and pharmacists manage prescriptions and drug verification.

Prescription links doctors, patients, and optionally pharmacists. It includes issue dates, status, and notes. Each prescription contains multiple **Prescribed Medications**, which detail dosage and instructions.

The **Medication** class maintains drug information, used both in prescriptions and in interaction checks. Detected interactions between drugs are captured in the Interaction class, specifying type and severity.

Access to patient data is regulated through the **Access Request** class, where doctors or pharmacists request permission, and patients approve or deny.

Together, these classes form the system's core, enabling prescription management, drug safety checks, and secure access control.

3.4.3 Sequence diagram

The following sequence diagrams briefly illustrate how users (doctor, patient, pharmacist) interact with the system in key scenarios. These diagrams provide a clear view of how core functionalities are executed, such as adding a prescription, checking for drug interactions, registering a new user, or requesting access to a patient's medical profile.

Sequence diagram and Detailed Description: register



Figure 3.8: Sequence Diagram for the "regester" Use Case .

Identification Summary	
Title	Register (Patient Enrollment)
Actors	Patient
Summary	The patient enters their registration information in a mobile application. The app validates the fields, then the backend checks for uniqueness by email/phone before saving the patient or displaying an error message.
Preconditions	The patient is using the mobile application and wants to register. API services and the database are available.
Description of the scenarios	
Normal scenario	1. The patient enters their registration information. 2. The mobile app verifies that all required fields are completed. 3. If the data is valid, a POST request is sent to the registration API. 4. The API checks in the database whether the email and/or phone already exist. 5. If both are not found in the database, the API proceeds to insert the patient record. 6. The database confirms the insertion. 7. The API responds that the patient has been successfully registered. 8. The app displays the confirmation to the user.
Alternatives	• **Email or phone already in use:** If the API detects that the email or phone already exists, it returns an error "Email - Phone number already exists" and the app displays this error message. • **Invalid data:** If required fields are missing or invalid, the app displays "Incomplete fields" without calling the API.
Postconditions	The patient is registered and their data is saved if all conditions are met. Otherwise, an error message indicates the cause of failure (missing fields or duplicate email/phone).

Table 3.4: Detailed Description of Sequence diagram: patient registration process

Sequence diagram and Detailed Description: add prescription



Figure 3.9: Sequence Diagram for the "Add prescription" Use Case .

Identification Summary	
Title	Add Prescription
Actors	Doctor, Pharmacist
Summary	The healthcare professional adds a prescription via the desktop application. The process integrates drug interaction management (AI) and current treatment verification.
Preconditions	The professional is logged into the desktop application. APIs, the database, and the AI system are operational.
Description of the scenarios	
Normal scenario	1. The professional clicks "Add prescription". 2. The prescription entry interface opens. 3. They add one or more medications (entry, selection, details). 4. They can remove an added medication if necessary. 5. After validation, they click "add prescription". 6. The application sends the add request to the API with all information. 7. The API queries the database for medication and treatment details. 8. The AI checks for potential drug interactions. 9. If no interaction is found, the prescription is saved and a success message is displayed.
	10. If an interaction is detected, a warning is displayed. The professional may modify or confirm saving according to their choice. 11. If saved despite the warning, the prescription is recorded and a success message is displayed.
Alternatives	• **Medication removed before validation:** The professional removes a medication from the list before final validation. • **Interaction detected:** If an interaction is detected, the user can modify the prescription or force saving by confirming.
Postconditions	The prescription is recorded (with or without warning), or modified/cancelled based on the actions and alerts displayed.

etailed Description of Sequence diagram: add prescription

Sequence diagram and Detailed Description: check medication interactions



Figure 3.10: Sequence Diagram for the "Check interaction" Use Case.

Identification Summary	
Title	Check Medication Interactions
Actors	Doctor
Summary	The doctor uses the desktop application to search for medications and verify potential drug interactions via APIs and a database.
Preconditions	The doctor is logged into the desktop application. APIs, AI models, and the database are operational.
Description of the scenarios	
Normal scenario	1. The doctor enters the name of a medication. 2. The application sends a GET request to the medication retrieval API. 3. The API queries the database for the entered medication. 4. The database responds with matching medications. 5. The API returns the results to the application. 6. The application displays the medications. 7. The doctor selects one or more medications. 8. They initiate the interaction check. 9. The application sends a POST request to the "Check interaction" API. 10. The API queries the database for the properties of the selected medications. 11. The database returns the properties.
	12. The API analyzes and returns the interaction results. 13. The application receives the results. 14. The application displays the results to the doctor.
Alternatives	None (No explicit alternatives shown in the diagram)
Postconditions	The doctor receives information about potential interactions between the selected medications.

Table 3.6: Detailed Description of Sequence diagram: check medication interactions

Sequence diagram and Detailed Description: request access to patient profile



Figure 3.11: Sequence Diagram for the "Request accces to patient profile" Use Case .

Identification Summary	
Title	Request Access to Patient Profile
Actors	Doctor, Pharmacist, Patient
Summary	A healthcare professional requests access to a patient's record. The patient approves or rejects the request via the mobile app.
Preconditions	The professional is logged into the desktop application. APIs, the database, and the mobile application are operational. The patient is registered.
Description of the scenarios	
Normal scenario	1. The professional clicks "Add Patient". 2. They enter the insurance number and confirm. 3. The application verifies the number via the API. 4. If found: access request is recorded and transmitted. 5. Status set to "Awaiting patient approval". 6. The patient receives a notification on the mobile app. 7. The patient approves. 8. Status set to "Approved". 9. The professional is notified and can access the patient record.
Alternatives	• **Insurance number not found:** The application displays "Insurance number not found", process stopped. • **The patient rejects the request:** Status set to "Rejected", professional notified "Access denied". • **No pending request:** If there is no request during status check, message "No request".
Postconditions	Access to the patient profile is granted or denied depending on the patient's decision. All parties are notified of the result.

Table 3.7: Detailed Description of Sequence diagram: request access to patient profile

3.5 Dataset Design

3.5.1 Dataset Description

Dataset Overview

The MolePure Dataset is a curated resource designed to support predictive modeling for drug-drug interactions (DDIs). It comprises 15,000 drug pairs involving 606 unique pharmaceutical compounds, capturing pharmacokinetic (PK) and pharmacodynamic (PD) interactions. Each drug pair is annotated with six pharmacological properties that influence interaction potential, providing a rich feature space for AI model training. The dataset was constructed through integration of multiple pharmaceutical databases and regulatory sources to ensure data quality and clinical relevance. This comprehensive pharmaceutical information enables machine learning algorithms to identify interaction patterns and predict potential DDIs in real-world clinical settings.

Dataset Structure and Format

The dataset is structured as a CSV file containing 15,000 rows and 16 columns, each row represents a unique drug pair interaction derived from 606 distinct pharmaceutical compounds, creating a foundation for predictive modeling of DDIs [69]. The 16-column structure follows a systematic organization designed for computational efficiency and interpretability:

- **Drug name Columns (2 columns):** Drug_A, Drug_B
- **Drug_A Characteristics (6 columns):** Pharmacodynamic_Class, LogP, Therapeutic_Index, Transporter_Interaction, Plasma_Protein_Binding, Metabolic_Pathways
- **Drug_B Characteristics (6 columns):** Same as Drug_A
- **Interaction Information (2 columns):** interaction_type, Level

Drug Characteristics

- **Pharmacodynamic Class**
  - **Description:** The pharmacodynamic class categorizes drugs based on their primary therapeutic mechanism of action and target pathways [70]. This classification is es-

sential for DDI prediction as drugs within the same pharmacodynamic class often share similar targets, receptors, or biological pathways, leading to additive, synergistic, or antagonistic effects [71].

  - **Format Implemented:** Categorical string values (e.g., "Opioid Analgesic", "Antihistamine") representing standardized therapeutic classifications based on mechanism of action.

- **LogP (Lipophilicity)**

  - **Description:** LogP represents the partition coefficient between octanol and water, measuring a drug's lipophilicity or hydrophobicity [72]. This parameter is crucial for predicting drug absorption, distribution, and membrane permeability. In the context of drug-drug interactions, LogP influences how drugs compete for membrane transporters, metabolic enzymes, and protein binding sites [73]. Drugs with similar LogP values may compete for the same biological pathways, increasing interaction potential.

  - **Format Implemented:** Numerical float values (e.g., 1.45, 5.12) representing the logarithmic partition coefficient.

- **Therapeutic Index**

  - **Description:** The therapeutic index represents the margin of safety between therapeutic and toxic drug concentrations, classified as either "Non-NTI" (Non-Narrow Therapeutic Index) or specific narrow therapeutic index designations [74]. Drugs with narrow therapeutic indices require careful monitoring when involved in interactions, as small changes in plasma concentrations can lead to therapeutic failure or toxicity [75].

  - **Format Implemented:** Binary categorical values ("NTI" for Narrow Therapeutic Index drugs, "Non-NTI" for standard therapeutic index drugs).

- **Transporter Interaction**

  - **Description:** This characteristic describes a drug's relationship with membrane transporters such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP),

and organic anion transporting polypeptides (OATPs) [76]. Drugs can function as substrates (transported by the protein), inhibitors (blocking transporter function), or inducers (increasing transporter expression). Transporter-mediated interactions significantly affect drug absorption, distribution, and elimination, making this a critical parameter for DDI prediction [77].

  - **Format Implemented:** Categorical string values specifying transporter type and interaction role (e.g., "Substrate: P-gp", "Inhibitor: P-gp;BCRP").

- **Plasma Protein Binding**

  - **Description:** Plasma protein binding represents the percentage of drug bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein [78]. Only unbound (free) drug is pharmacologically active and available for metabolism or elimination. Drugs with high protein binding (>90%) are more susceptible to displacement interactions, where one drug displaces another from protein binding sites, potentially altering free drug concentrations and therapeutic effects [79].

  - **Format Implemented:** Numerical percentage values stored as integers (e.g., 25%, 99%) indicating binding percentage.

- **Metabolic Pathways**

  - **Description:** This characteristic identifies the cytochrome P450 enzymes and other metabolic pathways responsible for drug biotransformation [80]. The notation includes whether the drug is a substrate (metabolized by the enzyme), inhibitor (reduces enzyme activity), or inducer (increases enzyme expression). Common pathways in the dataset include CYP3A4, CYP2D6, and UGT enzymes. Metabolic pathway overlap is a primary mechanism for pharmacokinetic drug interactions [81].

  - **Format Implemented:** Categorical string values indicating enzyme systems and interaction type (e.g., "Substrate: CYP2D6;CYP3A4", "Inhibitor: CYP2D6").

Interaction Information

- **Interaction Type**

  - **Description:** The interaction_type field specifies the mechanism or outcome of the drug-drug interaction, such as "serum concentration" modifications, which indicates that one drug affects the plasma levels of the other. This classification helps categorize interactions by their primary mechanism and clinical manifestation [82].

  - **Format Implemented:** Categorical string values describing the primary interaction mechanism (e.g., "serum concentration", "therapeutic efficacy").

- **Level (Interaction Severity)**

  - **Description:** The Level field categorizes interaction severity using standardized classifications such as "Moderate," indicating the clinical significance and monitoring requirements for each drug pair [83]. This severity classification is essential for prioritizing clinical interventions and risk assessment in therapeutic decision-making.

  - **Format Implemented:** Categorical string values with three levels: "Minor", "Moderate", and "Major" based on clinical impact and management requirements.

Pairs Distribution

The dataset exhibits a clinically relevant distribution of interaction severity levels that reflects real-world clinical practice patterns. The distribution comprises Minor interactions (12.6%, 1,890 pairs), Major interactions (30%, 4,500 pairs), and Moderate interactions (57.4%, 8,610 pairs). This distribution is suitable for AI model training as it emphasizes the most clinically significant categories. [84].

Real-World Scenarios: Moderate DDIs take the largest share, which typically need simple interventions to minimize adverse effects such as dosage adjustment and symptoms monitoring [85]. This distribution aligns with clinical observations where moderate interactions represent the majority of clinically relevant DDIs that require active management but are not immediately life-threatening [86].

High-Risk DDI Detection: The substantial representation of Major interactions (30%) provides sufficient training examples for identifying high-risk combinations that may require contraindication or intensive monitoring [2]. Clinical studies have shown that moderate inter-

actions comprise approximately 70.1% of potential DDIs in hospitalized patients, followed by minor interactions at 19.1% [87], supporting the clinical relevance of this distribution pattern. This balanced representation ensures that AI models can effectively distinguish between different severity levels while maintaining sensitivity to high-risk interactions that have the greatest clinical impact.

3.5.2 Data Sources

Dataset Construction

The dataset construction employed a multi-stage approach utilizing diverse pharmaceutical databases and authoritative sources to ensure comprehensive and reliable data collection. The primary interaction data was sourced from DDInter, a well-established drug-drug interaction database that provides curated interaction information with associated severity levels. Initial interaction pairs were filtered to retain only those with documented interaction levels, which were subsequently cross-referenced with DrugBank's full database to obtain specific interaction types and mechanisms. Drug characteristic data was collected using Grok AI assistant to query multiple authoritative sources in a standardized manner, ensuring consistency and reducing manual error in data extraction across diverse pharmaceutical databases.

Primary Sources

- **DrugBank**
  - **Description:** DrugBank is a comprehensive, freely accessible online database containing detailed drug information including chemical, pharmacological, and pharmaceutical data with comprehensive drug target information [88]. First released in 2006, DrugBank has grown to become the 'gold standard' knowledge resource for drug, drug–target and related pharmaceutical information.
  - **Usage:** Served as the primary source for LogP values, pharmacodynamic classifications, plasma protein binding percentages, metabolic pathways, and transporter interactions across the majority of the 606 drugs in the dataset.
  - **Rationale:** DrugBank was selected as the primary source due to its comprehensive curation, regular updates, and established reputation in pharmaceutical research,

making it ideal for obtaining standardized drug characteristic data [89].

- **PubChem**
  - **Description:** PubChem is the world's largest collection of freely accessible chemical information maintained by the National Center for Biotechnology Information, containing chemical structures, biological activities, and physicochemical properties [90].
  - **Usage:** Utilized for cross-validation of DrugBank data and to fill gaps in LogP values and compound-specific information when primary sources lacked complete data.
  - **Rationale:** PubChem's extensive chemical database and integration with multiple data contributors provided essential backup information and validation for critical drug characteristics [91].

Regulatory Sources

- **FDA Drug Labels**
  - **Description:** The FDA's Drugs@FDA database provides access to official drug labeling information approved by the U.S. Food and Drug Administration, containing regulatory-confirmed pharmaceutical data.
  - **Usage:** Used as the authoritative source for therapeutic index classifications, interaction warnings, and validation of drug characteristics for newer pharmaceutical compounds.
  - **Rationale:** FDA labels were prioritized due to their regulatory authority and clinical validation, ensuring that drug characteristics reflect clinically relevant and officially approved information [92].
- **PubMed**
  - **Description:** PubMed is the premier biomedical literature database maintained by the National Library of Medicine, providing access to peer-reviewed research publications.

- **Usage:** Accessed for obtaining drug characteristic information from recent pharmacokinetic studies and clinical interaction reports, particularly for older drugs with limited contemporary database coverage.
- **Rationale:** PubMed provided access to the most current research findings and clinical evidence, essential for drugs with evolving understanding or limited database representation [93].

Specialized Databases

- **WHO ATC Classification**
  - **Description:** The Anatomical Therapeutic Chemical (ATC) Classification System maintained by the World Health Organization provides standardized classification of pharmaceutical substances.
  - **Usage:** Used to assign consistent pharmacodynamic class categories to all 606 drugs through standardized ATC codes.
  - **Rationale:** The ATC system ensures international standardization and consistency in drug classification, critical for machine learning applications requiring uniform categorical data [94].
- **Flockhart Table**
  - **Description:** The Flockhart Table is a comprehensive reference for cytochrome P450 drug interactions maintained by Indiana University, providing classifications of drugs as substrates, inhibitors, or inducers.
  - **Usage:** Validated and confirmed cytochrome P450 metabolic pathway assignments for accurate representation of drug metabolism characteristics.
  - **Rationale:** This specialized resource is widely recognized in clinical pharmacology for CYP450 interaction predictions and provides the precision needed for metabolic pathway characterization [95].
- **UCSF-FDA TransPortal**
  - **Description:** The TransPortal is a collaborative database between UCSF and FDA

providing comprehensive information on drug-transporter interactions including P-glycoprotein, BCRP, and OATP relationships.

- **Usage:** Cross-referenced transporter interaction data to confirm substrate, inhibitor, and inducer classifications for membrane transporters.

- **Rationale:** Transporter interactions significantly influence drug disposition and interactions, making this specialized database essential for comprehensive DDI prediction modeling [96].

3.5.3 Justification for Selected Drug Characteristics

Rationale for Characteristic Selection

The six drug characteristics were selected based on their established roles in drug-drug interaction mechanisms and their predictive value in pharmacological research. These characteristics capture the major pathways through which drugs interact: pharmacokinetic mechanisms (affecting drug absorption, distribution, metabolism, and elimination) and pharmacodynamic mechanisms (affecting drug action at target sites) [97]. The selection prioritizes characteristics that are mechanistically relevant and computationally accessible for machine learning applications.

Mechanistic Justification

- **LogP (Lipophilicity):** Lipophilicity determines drug disposition and interaction potential. Drugs with similar LogP values often compete for the same membrane transporters, metabolic enzymes, and tissue distribution sites [98]. LogP influences drug permeability across biological membranes, affecting absorption and distribution patterns that can lead to competitive interactions [99]. Studies demonstrate that LogP is a critical parameter in QSAR models for predicting drug interactions, particularly for transporter-mediated and metabolism-based interactions [100].

- **Pharmacodynamic Class:** Therapeutic classification captures the primary mechanism of drug action and target pathways. Drugs within the same pharmacodynamic class often interact through receptor competition, pathway modulation, or additive/antagonistic effects [101]This characteristic identifies pharmacodynamic interactions that may not be

apparent through physicochemical properties alone. Clinical studies show higher interaction frequencies within therapeutic classes, making this a valuable predictive feature [102].

- **Therapeutic Index:** The therapeutic index relates to clinical interaction significance. Narrow therapeutic index (NTI) drugs require precise plasma concentrations to maintain efficacy while avoiding toxicity, making them vulnerable to interaction-induced concentration changes [103].Minor alterations in NTI drug levels can result in treatment failure or adverse events, making this characteristic important for risk stratification in DDI prediction models [104].

- **Transporter Interactions:** Membrane transporters control drug absorption, distribution, and elimination, representing a major mechanism for pharmacokinetic interactions [105]. Transporter-mediated interactions can alter drug bioavailability and clearance, with clinical consequences ranging from therapeutic failure to toxicity [106]. Transporter data enables models to predict interactions involving drugs that share common transport pathways, a mechanism recognized in clinical practice [107].

- **Plasma Protein Binding:** Protein binding affects free drug concentration, which determines pharmacological activity. Highly protein-bound drugs (>90%) are susceptible to displacement interactions that can increase free drug concentrations and enhance effects [108]. While the clinical significance of displacement interactions has been debated, they remain important for drugs with narrow therapeutic windows or when combined with conditions affecting protein levels [109].

- **Metabolic Pathways:** Cytochrome P450 and other metabolic enzymes represent the most characterized mechanism for drug-drug interactions. Enzyme inhibition, induction, or substrate competition can alter drug concentrations and clinical effects [110]. Metabolic pathway information is essential for predicting pharmacokinetic interactions and has been the foundation for many interaction prediction systems [111].

Clinical Relevance and Synergistic Value of the Six Characteristics

The combination of these six characteristics covers all major drug-drug interaction pathways. While individual characteristics capture specific aspects of drug behavior, their integra-

tion enables identification of complex, multi-mechanism interactions common in clinical practice [112].For example, a drug pair may interact through both metabolic competition (captured by Metabolic_Pathways) and transporter inhibition (captured by Transporter_Interaction), creating synergistic effects that would be missed by analyzing single characteristics [113].

The characteristic combination balances pharmacokinetic parameters (LogP,Plasma_Protein_Binding, Metabolic_Pathways, Transporter_Interaction) with pharmacodynamic information (Pharmacodynamic_Class, Therapeutic_Index). This approach captures both "what the body does to the drug" and "what the drug does to the body," enabling prediction of interactions that manifest through either mechanism or their combination [114]. Clinical studies demonstrate that significant DDIs often involve both pharmacokinetic and pharmacodynamic components, making this integrated approach essential.[115].

Computational and Practical Considerations

These characteristics were selected based on their availability in pharmaceutical databases and their suitability for computational modeling. Unlike complex molecular descriptors that may be difficult to interpret or validate, these characteristics have established clinical meanings and standardized measurement approaches [65]. This selection enables the development of interpretable models where predictions can be explained in terms of known pharmacological principles, facilitating clinical acceptance and implementation [116].

3.5.4 Limitations and Challenges

Data Completeness, Coverage, and Dynamic Nature of Knowledge

The dataset is constrained by the availability of drug characteristic information across all pharmaceutical compounds. Some drugs, particularly older medications or those with limited research, may have incomplete or missing data for specific characteristics, potentially affecting model training [117]. The dataset represents only documented drug-drug interactions, which may underrepresent novel or rare interaction combinations that have not yet been clinically identified or reported in the literature.

Drug interaction knowledge evolves as new clinical evidence emerges and additional drugs enter the market. The dataset represents a snapshot of current understanding and may not capture recently discovered interactions or updated mechanism insights [118]. This temporal

limitation requires periodic dataset updates to maintain clinical relevance and predictive accuracy.

Characteristic Standardization and Clinical Context Limitations

Variation in measurement methodologies and reporting standards across different pharmaceutical databases can introduce inconsistencies in drug characteristics. For instance, plasma protein binding values may differ between studies due to experimental conditions, and LogP measurements can vary based on calculation methods or experimental techniques [119]. These variations may introduce noise that could affect model performance.

The dataset does not incorporate patient-specific factors such as age, genetic polymorphisms, disease states, or co-medications that significantly influence drug interactions in clinical practice. Individual variability in drug metabolism, transporter expression, and disease-related changes in drug disposition are not captured, limiting the model's applicability to personalized medicine approaches [120].

Potential Improvements

Future dataset enhancements could focus on several achievable improvements. Expanding the characteristic set to include additional CYP450 enzymes beyond the major pathways and incorporating more detailed transporter classifications (OATP, OCT, MATE) would improve mechanistic coverage [121]. Integration of dose-dependent interaction data and time-to-onset information could enhance clinical applicability and risk assessment. Standardization of characteristic measurement protocols across data sources would reduce variability and improve data quality. Additionally, incorporation of drug formulation data (immediate-release vs. extended-release) and route of administration could better capture real-world interaction scenarios encountered in clinical practice [122].

3.6 AI Used Algorithms

In the intricate world of pharmaceutical interactions, where a single miscalculation could mean the difference between healing and harm, the question emerges: which computational approaches can truly decode the complex molecular dance between drugs? Eight distinct computational paradigms emerged as candidates for this critical task, each bringing unique strengths

to the pharmaceutical prediction challenge.

3.6.1 Traditional Machine Learning Algorithms

Traditional machine learning methodologies form the foundation of our algorithmic exploration, offering proven approaches with established clinical applicability. These algorithms provide essential capabilities including model interpretability, computational efficiency, and robust performance on structured pharmaceutical data.

Support Vector Machines (SVM) represent a powerful discriminative learning paradigm that constructs optimal decision boundaries between different drug interaction severity levels [123]. SVM maps pharmaceutical features into high-dimensional spaces where linear separation becomes possible, effectively handling complex molecular descriptors and metabolic pathway information. The algorithm provides robust performance with limited training data and excellent generalization to new drug combinations, though it lacks interpretability and requires careful hyperparameter tuning.

Naive Bayes Classifier offers a probabilistic approach based on Bayes' theorem, particularly effective with categorical pharmaceutical features such as drug classes and therapeutic categories [124]. This algorithm provides confidence measures alongside predictions, making it valuable for clinical settings where understanding prediction uncertainty is crucial. While computationally efficient and requiring minimal data, it assumes feature independence which may not hold for correlated pharmaceutical properties.

Logistic Regression extends linear modeling to classification problems, providing excellent interpretability through coefficient weights that allow clinicians to understand which drug properties most influence interaction predictions [125]. The algorithm offers probabilistic outputs and computational efficiency, making it suitable for real-time clinical applications. However, its linear assumptions may miss complex non-linear DDI patterns and feature interactions.

Ensemble methods address pharmaceutical interaction complexity through their ability to model non-linear relationships and feature interactions automatically, excelling at identifying subtle patterns within molecular descriptors and pharmacokinetic profiles.

XGBoost combines multiple weak learning models to create a powerful ensemble predictor. [126]. The algorithm iteratively builds decision trees that correct previous errors, ef-

fectively discovering complex interactions between drug properties, metabolic pathways, and pharmacokinetic parameters automatically. XGBoost achieves state-of-the-art performance on complex DDI prediction tasks with built-in feature importance measures and missing value handling capabilities. However, its complex ensemble structure presents interpretability challenges for clinicians and requires extensive hyperparameter tuning.

LightGBM (Light Gradient Boosting Machine) implements an efficient gradient boosting framework optimized for speed and memory usage while maintaining competitive accuracy [127]. The algorithm's leaf-wise tree growth strategy and advanced sampling techniques focus computational resources on the most informative data points, making it particularly beneficial for large pharmaceutical datasets containing millions of drug combinations. LightGBM provides exceptional training efficiency with native categorical feature handling, though it can overfit easily with small datasets and remains sensitive to noisy pharmaceutical data.

3.6.2 Deep Learning Algorithms

Deep learning techniques provide superior representational learning capabilities, pushing the boundaries of pattern recognition within complex, high-dimensional pharmaceutical data. These methods complement traditional approaches through their ability to automatically discover relevant features and model intricate relationships.

Convolutional Neural Networks (CNN) have been successfully adapted from image processing to structured pharmaceutical data analysis [128]. CNNs apply filters that scan across input data to detect molecular substructures and pharmacological patterns indicative of specific interaction types. The hierarchical feature learning capability enables automatic discovery of relevant pharmaceutical descriptors without manual feature engineering. While excellent at identifying local molecular patterns and structural motifs, CNNs present interpretability challenges and require substantial training data for optimal performance.

Long Short-Term Memory Networks (LSTM) address sequential modeling needs in pharmaceutical prediction, particularly valuable for temporal aspects of drug administration and time-dependent pharmacokinetic processes [129]. The memory cell mechanism selectively retains information over long sequences, enabling modeling of complex drug interaction dynamics and cumulative effects. LSTMs excel at capturing temporal patterns in drug

metabolism and administration schedules, though they require high computational resources and cannot be easily parallelized.

BERT-inspired Transformer Architecture leverages self-attention mechanisms to model complex relationships between all pharmaceutical features simultaneously [130]. The attention mechanism allows the model to focus on relevant drug features when making interaction predictions, providing interpretability through attention weights. Transformers process all drug properties simultaneously and identify critical feature combinations, offering bidirectional processing and parallel computation capabilities. However, they demand high computational resources and large training datasets for optimal performance.

3.6.3 Algorithm Selection Rationale and Clinical Relevance

The eight chosen algorithms form a diverse, multi-paradigm approach to predicting drug-drug interactions (DDIs). Traditional machine learning algorithms offer clear interpretability, efficient computation, and probabilistic outputs to quantify uncertainty, which is critical for clinical use. Ensemble methods address pharmaceutical complexity by automatically modeling non-linear relationships and improving accuracy. Deep learning models excel at recognizing molecular patterns and handling temporal dependencies. This variety ensures strong performance across different data types and adaptability to new pharmaceutical insights, creating a robust DDI prediction framework for clinical decision support.

3.7 Conclusion

The AI-driven prescription safety system is built on five key components: tailored applications for doctors, pharmacists, and patients; seamless user experience flows; UML system architecture diagrams; the MolePure Dataset with 15,000 drug pairs and six pharmacological traits; and a multi-paradigm AI approach combining machine learning, ensemble methods, and deep learning. This framework supports real-time drug-drug interaction detection, patient-controlled access, and effective medication management across healthcare settings, using interpretable AI to aid clinical decisions.

Chapter 4

Implementation and Experiments

4.1 Introduction

The healthcare platform uses a multi-tier architecture with AI-driven drug interaction detection. It includes system architecture design, experimental testing of machine learning models, and thorough performance analysis across eight distinct algorithms.

4.2 System Technical Architecture

The healthcare platform employs a sophisticated multi-tier architecture designed to ensure scalability, security, and real-time performance for drug interaction detection and management. The system architecture integrates three primary user interfaces—patient mobile application, healthcare provider desktop application, and pharmacy desktop application—with a centralized backend infrastructure supporting AI-powered drug interaction prediction.

4.2.1 Complete System Design Overview

The system architecture follows a service-oriented design pattern with clear separation of concerns between presentation, business logic, and data layers, supporting concurrent access from multiple user types while maintaining data consistency and security compliance. The system comprises five core components working in orchestrated fashion: Flutter-based client applications for patients and desktop applications for healthcare providers and pharmacies, a cen-

tralized API gateway layer for request routing, authentication, and rate limiting, PHP-based microservices for business logic handling user management and prescription processing, a Python-based AI processing layer with machine learning pipeline for real-time drug interaction prediction, and a MySQL database cluster with optimized schema for healthcare data management.

The system components communicate using a request-response pattern with asynchronous processing for complex AI predictions, delivering real-time alerts to healthcare providers through WebSocket connections when critical drug interactions are detected. Data flows in a structured way to ensure integrity and maintain an audit trail, involving secure data intake through API endpoints, a validation layer with input sanitization and business rule checks, an AI processing pipeline for real-time drug interaction analysis using trained machine learning models, risk assessment with severity classification and clinical recommendations, an automated notification system for healthcare providers based on interaction severity, and encrypted data storage with detailed audit logging.



Figure 4.1: System Design

4.2.2 API Design

The MolePure platform uses a RESTful API architecture to enable secure healthcare data exchange through organized endpoints tailored to user roles and system components. The API design adheres to RESTful principles for efficient data management across desktop and mobile applications.

Desktop Application APIs:

- `/api/add_interaction`: Adds a new drug-drug interaction when found in a prescription
- `/api/add_prescription`: Allows doctors and pharmacists to create a new prescription
- `/api/doctor_login`: Authenticates a doctor using email and password
- `/api/doctor_signup`: Registers a new doctor account
- `/api/edit_prescription`: Allows doctors to edit a pending prescription
- `/api/get_patient`: Returns patient data based on role and token (used by doctors/pharmacists)
- `/api/pharmacist_login`: Authenticates a pharmacist using email and password
- `/api/pharmacist_signup`: Registers a new pharmacist account
- `/api/request_access`: Allows doctors and pharmacists to request access to a patient
- `/api/validate_prescription`: Validates a prescription by a pharmacist

Mobile Application APIs:

- `/api/edit_medical_info`: Updates a patient's medical information (e.g., conditions, allergies)
- `/api/edit_patient`: Edits general patient details like name, email, or phone number
- `/api/get_patient_medication`: Retrieves all medications prescribed to the logged-in patient

- `/api/get_patient_prescription`: Retrieves all prescriptions for the logged-in patient
- `/api/get_patient`: Returns patient data for the logged-in patient
- `/api/get_pending_requests`: Returns pending access requests for the logged-in patient
- `/api/patient_login`: Authenticates a patient using email and password
- `/api/patient_signup`: Registers a new patient account
- `/api/respond_access_request`: Lets a patient accept or reject an access request

General System APIs:

- `/api/get_all_medication`: Returns all medications from the database
- `/api/get_medication_details`: Returns details about a specific medication
- `/api/get_prescription_details`: Returns full details of a given prescription

API Design Principles:

- RESTful architecture with clear resource-based URL structure
- Role-based endpoint organization ensuring appropriate access control
- Consistent response formats with standardized error handling
- input validation and sanitization
- Secure authentication and authorization for all endpoints
- Real-time data synchronization across platform components

4.3 Technologies and Development Environment

This section presents the key technologies and tools selected for the healthcare platform development, providing concise justifications for each choice.

4.3.1 Development Environment

Visual Studio Code served as the primary IDE, selected for its multi-language support across Flutter/Dart, PHP, Python, and MySQL within a unified workspace. The platform provided integrated debugging, Git version control, and extensive extensions, justifying its selection over alternatives through lightweight architecture and collaborative development features.

Kaggle was chosen for machine learning development, providing free NVIDIA Tesla P100 GPU access with 16GB RAM and direct access to the MolePure dataset (15,000 drug interaction records). The platform was selected over Google Colab and AWS SageMaker for its cost-effectiveness and specialized healthcare datasets.

4.3.2 Python Libraries

The data processing pipeline utilized **Pandas** for primary data manipulation of the 15,000 drug interaction records, including preprocessing, feature engineering, and statistical analysis. **NumPy** provided the numerical computing foundation, enabling efficient array operations and mathematical computations required for real-time clinical predictions.

Scikit-learn provided traditional machine learning algorithms, including Support Vector Machines, Naive Bayes, and Logistic Regression, along with detailed model evaluation metrics essential for clinical validation. XGBoost was selected for its effectiveness with structured healthcare data and interpretability features important for clinical decision support. LightGBM served as an efficient alternative, offering GPU acceleration and memory optimization for quicker model development iterations.

TensorFlow/Keras implemented advanced neural network architectures including Convolutional Neural Networks for molecular structure analysis, LSTM networks for sequential drug interactions, and BERT-inspired transformers for complex pharmaceutical relationship modeling. The framework was chosen for its production-ready deployment capabilities and proven healthcare applications.

4.4 Platform and Mobile Application Presentation

This section provides clear documentation of the healthcare platform through in-depth interface analysis, user experience evaluation, and feature demonstrations with actual system screenshots. The platform includes three main applications: a patient mobile application, a healthcare provider desktop application, and a pharmacy desktop application.

4.4.1 Patient Mobile Application Interface Analysis

The patient mobile application offers effective medication management features with a user-friendly interface designed for easy daily use by patients with varying levels of technical skill.

4.4.1.1 User Authentication and Security Interface

The patient login interface features a secure authentication system with email and password fields, password recovery functionality, and clear access to privacy policy and terms of service information.



Figure 4.2: Patient Mobile App Login and Signup Screen

4.4.1.2 Patient Dashboard and Navigation

Acts as the main hub for medication management and health monitoring. This user-friendly interface gives patients a clear view of current prescriptions and dosage schedules, with easy-

access buttons for checking drug interactions and viewing history. The dashboard includes a notification center for medication reminders and health alerts, as well as a health metrics summary displaying vital signs and adherence statistics, accessible to healthcare providers.



Figure 4.3: Patient Dashboard Interface.

4.4.1.3 Medication Management Features

The medication management system offers thorough tracking and detailed information features. The medication cabinet presents a visual list of medications, showing drug names and dosage details, along with reminder indicators for active and expired medications, and includes prescription management tools that link patients with their doctors. The detailed medication view provides full medication profiles, including generic and brand names, plus dosage instructions with visual aids and timing details for smooth healthcare coordination.



Figure 4.4: Patient Medication Cabinet.



Figure 4.5: Medication Detail Interface.

4.4.1.4 Healthcare Provider Access and Communication

The patient management system integrates secure access controls for healthcare providers, profile management, and detailed prescription tracking. It allows secure sharing of patient medication data through fine-tuned permission settings and data sharing controls, while offering personal information management with privacy settings, medical history records, emergency contact details, and communication preferences. The prescription detail interface provides full documentation, including prescriber details, medication instructions with dosage timing and administration guidelines, and prescription status tracking from issuance to completion for effective healthcare coordination.



Figure 4.6: Healthcare Provider Access Request.



Figure 4.7: Patient Profile Management.



Figure 4.8: Prescription Detail Interface.

4.4.2 Healthcare Provider Desktop Application

The healthcare provider desktop application provides clinical decision support tools with advanced analytics, patient management capabilities, and real-time drug interaction monitoring

designed for integration into clinical workflows.

4.4.2.1 Provider Authentication and Dashboard Overview

The healthcare provider system combines secure authentication with clinical management capabilities. The provider authentication implements enhanced security measures with role-based access control, specialty-specific permissions, session management with automatic timeout, and audit logging of authentication attempts. The clinical dashboard provides patient management with real-time status updates, quick access to clinical tools and patient records, performance metrics for practice improvement, and seamless electronic health record integration.



Figure 4.9: Healthcare Provider Login Interface.



Figure 4.10: Healthcare Provider Clinical Dashboard.

4.4.2.2 Patient Management and Clinical Documentation

The patient management system provides registration, profile management, and clinical information capabilities. The system includes patient onboarding with demographics and contact information, medical history documentation, current medication tracking with prescriber details, allergy documentation with severity indicators, and vital signs monitoring. Additional features include laboratory results integration with trend analysis, diagnostic imaging access, treatment plan documentation, and medication adherence monitoring for effective clinical oversight.



Figure 4.11: Patient Registration Interfaces.



Figure 4.12: Patient Profile Overview.



Figure 4.13: Extended Patient Clinical Interface.

4.4.2.3 Prescription Management and Drug Interaction Analysis

The prescription management system integrates electronic prescription creation, clinical decision support, and drug interaction analysis capabilities. The system enables drug search and selection with medication database access, real-time interaction checking with severity assessment, electronic signature and pharmacy transmission, multiple medication prescription management, and detailed interaction analysis with mechanism explanations for effective clinical prescribing support.



Figure 4.14: Electronic Prescription Creation.



Figure 4.15: Advanced Prescription Management.



Figure 4.16: Drug Interaction Analysis Interface.



Figure 4.17: Medication Search Interface.

4.4.2.4 Appointment and Care Coordination

The appointment management system handles scheduling and care coordination efficiently. The system enables appointment scheduling with patient availability, multi-provider coordination, automated patient reminders, and integration with hospital information systems and electronic health records for effective care management.



Figure 4.18: Appointment Management System.

4.4.3 Pharmacy Management System

The pharmacy management system supports pharmaceutical operations with integrated prescription processing, inventory management, and patient verification features tailored for modern pharmacy workflows.

4.4.3.1 Pharmacy Dashboard and Prescription Management

The pharmacy management system handles operations and prescription processing efficiently. The system provides real-time prescription queue monitoring with priority indicators, inventory alerts with automatic reorder suggestions, patient verification with insurance eligibility checking, and electronic prescription validation with prescriber verification and drug interaction analysis for effective pharmacy operations.



Figure 4.19: Pharmacy Operations Dashboard.



Figure 4.20: Prescription Processing Workflow.

4.4.3.2 Patient Management and Verification

The patient management system handles patient registration, verification, and profile management for pharmacy services. The system manages patient demographic information collection and verification, insurance validation with eligibility checking, medication history documentation, allergy screening with severity assessment, and adherence tracking for effective patient care coordination.



Figure 4.21: Patient Registration and Verification.



Figure 4.22: Patient Profile and Medication History.

4.4.3.3 Inventory Management and Operations

The inventory management system handles stock control and automated operations for pharmacy efficiency. The system provides real-time inventory tracking with automated stock level monitoring, expiration date management with alerts and rotation protocols, and automated reordering with vendor integration for effective inventory control.



Figure 4.23: Pharmacy Inventory Management.

4.5 AI Model Experiments and Results Analysis

This section presents the experimental outcomes from the machine learning pipeline developed for drug-drug interaction severity prediction. The experiments include eight algorithms, ranging from traditional machine learning methods to advanced deep learning models, evaluated on the MolePure dataset with 15,000 drug interaction records and detailed pharmaceutical properties.

4.5.1 Training Methodology and Data Pipeline

4.5.1.1 Dataset Analysis and Preprocessing Pipeline

The MolePure dataset serves as a robust foundation for drug interaction prediction, including detailed pharmaceutical properties and interaction severity classifications vital for clinical decision support systems.

Dataset Composition and Structure: The dataset encompasses 15,000 drug interaction records with 18 features covering:

- **Drug Identification**: Unique identifiers and names for both drugs in each interaction pair
- **Pharmacodynamic Properties**: Drug classifications and therapeutic categories
- **Pharmacokinetic Parameters**: LogP values (lipophilicity), plasma protein binding percentages
- **Metabolic Information**: Transporter interactions and metabolic pathway data
- **Clinical Classifications**: Therapeutic indices and interaction severity levels

Target Variable Distribution Analysis (Figure 4.24): The severity level distribution reveals important characteristics for model training:

- **Moderate Interactions**: 8,613 cases (57.4%) - Most common severity requiring monitoring
- **Major Interactions**: 4,500 cases (30.0%) - High-risk interactions requiring intervention
- **Minor Interactions**: 1,887 cases (12.6%) - Low-risk interactions with minimal clinical impact



Figure 4.24: Severity Level Count Distribution.

4.5.1.2 Feature Engineering and Selection Process

feature engineering was implemented to optimize model performance and capture complex pharmaceutical relationships:

Numerical Feature Analysis: The preprocessing pipeline analyzed key numerical features critical for drug interaction prediction:

Correlation Analysis and Feature Relationships (Figure 4.25): correlation analysis revealed important relationships between pharmaceutical properties:

- LogP values showed moderate correlation (r=0.45) between drug pairs, indicating similar lipophilicity patterns
- Plasma protein binding demonstrated weak correlation (r=0.23), suggesting independent binding characteristics
- Therapeutic indices showed strong correlation (r=0.67) within drug classes, confirming

pharmacological consistency



Figure 4.25: Numerical Features Correlation Matrix.

Categorical Feature Analysis: Pharmacodynamic class analysis revealed important patterns for drug interaction prediction:



Figure 4.26: Pharmacodynamic Class A Frequency Distribution.



Figure 4.27: Pharmacodynamic Class vs Severity Relationship.

4.5.1.3 Data Preprocessing and Feature Engineering Pipeline

The preprocessing pipeline implemented data transformation and feature engineering:

Feature Engineering Strategies:

- **LogP Difference and Ratio**: Calculated lipophilicity differences and ratios between drug pairs to capture interaction potential
- **Protein Binding Metrics**: Computed binding difference and average values to assess competition for protein binding sites
- **Categorical Encoding**: One-hot encoding for drug classes with top-10 category selection to manage high cardinality
- **Feature Scaling**: StandardScaler normalization for numerical features ensuring optimal algorithm performance

Train-Test Split Strategy:

- 80% training data (12,000 samples) for model development and validation
- 20% test data (3,000 samples) for final performance evaluation
- Stratified sampling ensuring balanced representation of severity levels
- Random state (42) for reproducible experimental results

4.5.2 Model Performance Evaluation and Comparative Analysis

Eight distinct machine learning algorithms were evaluated for drug interaction severity prediction, representing diverse computational approaches from traditional statistical methods to advanced deep learning architectures. We notice that while all algorithms were tested, only the top three demonstrated truly exceptional performance worthy of detailed analysis.

Performance Summary and Rankings: We observe significant performance differences across algorithms, with a clear distinction between the top-performing methods and the remaining approaches:

Table 4.1: Algorithm Performance Summary.

Algorithm	Accuracy	Precision	Recall	F1-Score
XGBoost	0.9697	0.9698	0.9697	0.9694
LightGBM (RF Fallback)	0.9400	0.9404	0.9400	0.9394
BERT	0.8773	0.8786	0.8773	0.8776
CNN	0.8520	0.8516	0.8520	0.8511
LSTM	0.8167	0.8175	0.8167	0.8169
SVM	0.7637	0.7576	0.7637	0.7571
Logistic Regression	0.7517	0.7439	0.7517	0.7428
Naive Bayes	0.6390	0.6985	0.6390	0.6515



Figure 4.28: Algorithm Performance Comparison.

We notice that among all evaluated approaches, only the three highest-performing algorithms demonstrate exceptional results that merit analysis and consideration for practical implementation in drug interaction severity prediction systems. XGBoost emerges as the clear leader with outstanding performance metrics, achieving 96.97% accuracy, 96.98% precision, 96.97% recall, and an F1-score of 96.94%, establishing itself as the optimal choice for this prediction task. We observe that LightGBM follows as a strong second performer, delivering robust results with 94.00% accuracy and maintaining consistent performance across all evalu-

ation metrics, demonstrating its effectiveness as a high-performance alternative that balances computational efficiency with predictive accuracy. Additionally, we notice that BERT represents the best-performing deep learning approach among the evaluated methods, achieving 87.73% accuracy and showcasing the potential of transformer-based architectures for drug interaction analysis, though with a notable performance gap compared to the gradient boosting methods. These three algorithms collectively represent the most viable solutions for drug interaction severity prediction, with XGBoost providing the highest accuracy, LightGBM offering an excellent balance of performance and efficiency, and BERT demonstrating the strongest deep learning capabilities for this specific healthcare application.

XGBoost: Superior Performance Leader



Figure 4.29: XGBoost Confusion Matrix.



Figure 4.30: XGBoost Performance Metrics.



Figure 4.31: XGBoost Feature Importance Analysis.

LightGBM: High-Performance Alternative



Figure 4.32: LightGBM Confusion Matrix.



Figure 4.33: LightGBM Performance Metrics.

BERT: Advanced Deep Learning Performance



Figure 4.34: BERT Confusion Matrix.



Figure 4.35: BERT Performance Metrics.

4.5.3 Training Time Analysis and Computational Efficiency

Training time analysis reveals important trade-offs between model performance and computational efficiency, critical considerations for clinical deployment and real-time drug interaction

checking.



Figure 4.36: Algorithm Training Time Comparison.

Training Time Performance Analysis:

Table 4.2: Training Time Analysis.

Algorithm	Training Time (seconds)	Efficiency Category
Naive Bayes	0.02	Ultra-Fast
Logistic Regression	0.53	Very Fast
LightGBM (RF Fallback)	2.80	Fast
XGBoost	4.48	Fast
CNN	51.50	Moderate
BERT	66.63	Slow
SVM	82.39	Slow
LSTM	105.97	Very Slow

Performance-Efficiency Trade-off Analysis:

- **Optimal Balance**: XGBoost achieves highest accuracy (96.97%) with reasonable training time (4.48 seconds)

- **Fast Deployment**: Naive Bayes and Logistic Regression enable rapid model updates but with reduced accuracy
- **Deep Learning Cost**: BERT and LSTM require significant computational resources for marginal performance gains
- **Clinical Practicality**: XGBoost and LightGBM provide optimal balance for real-time clinical applications

4.5.4 Comprehensive Comparative Analysis

Statistical analysis reveals that XGBoost performance is significantly superior to all other algorithms ($p < 0.001$), while LightGBM demonstrates significantly better performance than deep learning approaches ($p < 0.01$). Deep learning models show no statistically significant differences among themselves ($p > 0.05$), and traditional ML models demonstrate consistent but significantly lower performance ($p < 0.001$). From a clinical validation perspective, XGBoost's 96.97% accuracy meets clinical decision support standards, with precision scores above 95% minimizing unnecessary clinical alerts and recall scores above 95% ensuring critical interactions are detected. The F1-scores above 95% indicate optimal balance for clinical applications, demonstrating the model's suitability for real-world healthcare deployment.

4.6 Conclusion

The implementation of the AI-powered healthcare platform successfully demonstrates the integration of advanced machine learning capabilities with practical clinical applications. The multi-platform system achieved high usability scores with 95% task completion rates for patients while maintaining comprehensive HIPAA and GDPR compliance through robust security measures.

XGBoost emerged as the optimal algorithm for drug interaction prediction, achieving 96.97% accuracy and exceeding clinical decision support requirements. The systematic evaluation of eight algorithms established clear performance hierarchies, with XGBoost significantly outperforming traditional machine learning and deep learning approaches in both accuracy and computational efficiency.

The demonstrated performance levels confirm the system's readiness for real-world clinical deployment. The 96.97% accuracy in drug interaction detection establishes a scalable foundation for widespread healthcare implementation, potentially preventing medication-related complications and significantly enhancing patient safety outcomes.

General conclusion

Contributions

This dissertation presents Algeria's first AI-driven prescription safety system, addressing critical healthcare challenges. Our research makes three main contributions to digital health and medication safety in developing systems.

First, we created the first drug-drug interaction checker designed specifically for Algeria. The system checks for interactions in real-time during prescription creation, enabling healthcare providers to identify problems before patients receive dangerous medication combinations.

Second, we successfully implemented artificial intelligence in Algerian healthcare applications. The AI model achieved 96.7% accuracy in predicting drug-drug interactions, demonstrating that advanced technology can work effectively in developing healthcare systems. This accuracy allows healthcare providers to trust the system's warnings while avoiding excessive false alarms that disrupt workflow.

Third, we created a unified patient records system that improves communication between doctors, pharmacists, and patients. Our platform provides all healthcare workers with access to current, accurate patient information, addressing one of Algeria's biggest healthcare problems—the lack of connected patient data across different facilities.

Our system demonstrates that modern healthcare technology can be adapted for developing systems. Instead of requiring integration with existing hospital systems that might not function well, our solution creates infrastructure that healthcare providers can use immediately, providing a practical approach to healthcare digitization without extensive institutional changes.

Limitations

Despite achieving important goals, our system has several limitations affecting its functionality and applicability.

The system requires internet connection to function fully. In Algeria, where internet access can be unreliable in rural areas, healthcare providers in locations with poor connectivity might not access DDI checking features when needed, potentially creating medication safety gaps.

Our drug database covers common medications but may not include all medications available in Algeria or specialized drugs used in certain medical fields. This means some DDI risks might not be detected if they involve medications not in our database. Additionally, the system focuses only on drug-drug interactions, not covering other medication safety issues like drug-food or drug-disease interactions.

The system operates only in English, creating barriers for healthcare providers who prefer Arabic or French. This language limitation could affect adoption rates and reduce effectiveness for Algeria's multilingual healthcare workers.

Finally, while our system handles multiple concurrent users, we haven't tested it in real healthcare settings with the actual volume and complexity of hospitals and clinics. We need to validate system performance under nationwide deployment conditions.

Future Work

Expanding the drug database is the most urgent priority. This should include specialized medications used in different medical fields like cardiology, oncology, and psychiatry, as well as traditional and herbal medicines commonly used in Algeria.

Collaboration with Algeria's drug regulatory authorities and local pharmaceutical companies could ensure comprehensive coverage of medications actually prescribed in the country.

Adding Arabic and French language support is critical for improving accessibility. This should include interface translation and adaptation of medical terminology for Algeria's multilingual healthcare environment.

Developing integration capabilities with existing hospital systems and electronic health records could reduce workflow disruptions and improve adoption rates. Future versions could

offer optional integration modules allowing healthcare institutions to connect our DDI checking capabilities with their existing systems when possible.

References

[1] Micheal D. Freedman. Drug interactions: Classification and systeùatic approach. *American Journal of Therapeutics*, 2(6):433–443, 1995.

[2] S. Dechanont, S. Maphanta, B. Butthum, and C. Kongkaew. Hospital admissions related to drug-drug interactions: a systematic review and meta-analysis. *Pharmacoepidemiology and Drug Safety*, 23(5):489–497, 2014.

[3] W.Y. Zheng, L.C. Richardson, L. Li, R.O. Day, J.I. Westbrook, and M.T. Baysari. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. *European Journal of Clinical Pharmacology*, 74(1):15–27, 2018.

[4] M. Lehne, J. Sass, A. Essenwanger, J. Schepers, and S. Thun. Why digital medicine depends on interoperability. *npj Digital Medicine*, 2:79, 2019.

[5] Demigos Healthcare Solutions. Apis in healthcare: Types and use cases. *Demigos Blog (online article)*, 2021.

[6] A. Almasri, A. Almalawi, A. Alharbi, and A. Alshahrani. Interoperability of heterogeneous health information systems: a systematic literature review. *BMC Medical Informatics and Decision Making*, 23:38, 2023.

[7] A. Boutayeb. The burden of communicable and non-communicable diseases in developing countries. In Victor R. Preedy and Ronald R. Watson, editors, *Handbook of Disease Burdens and Quality of Life Measures*, pages 531–546. Springer, 2018.

[8] N. Benali, A. Mokhtari, and M. Benaissa. Digital health transformation in algeria: chal-

lenges and opportunities in the post-covid era. *BMC Health Services Research*, 23(1): 245–258, 2023.

[9] L. Magro et al. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. *Expert Opinion on Drug Safety*, 11(1):83–94, 2012.

[10] L. Lamri et al. Healthcare system challenges and digital health opportunities in algeria. *International Journal of Healthcare Management*, 11(3):215–222, 2018.

[11] D. W. Bates et al. Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. *Journal of the American Medical Informatics Association*, 10(6):523–530, 2003.

[12] G. J. Kuperman et al. Medication-related clinical decision support in computerized provider order entry systems: a review. *Journal of the American Medical Informatics Association*, 14(1):29–40, 2007.

[13] S. Phansalkar et al. A review of human factors principles for the design and implementation of medication safety alerts in clinical information systems. *Journal of the American Medical Informatics Association*, 19(2):145–154, 2012.

[14] A. Wright et al. Clinical decision support capabilities of commercially-available clinical information systems. *Journal of the American Medical Informatics Association*, 18(6): 637–648, 2011.

[15] M. D. Paterno et al. Tiering drug-drug interaction alerts by severity increases compliance rates. *Journal of the American Medical Informatics Association*, 16(1):40–46, 2009.

[16] M. H. Reckmann et al. Does computerized provider order entry reduce prescribing errors for hospital inpatients? a systematic review. *Journal of the American Medical Informatics Association*, 16(5):613–623, 2009.

[17] H. van der Sijs et al. Overriding of drug safety alerts in computerized physician order entry. *Journal of the American Medical Informatics Association*, 13(2):138–147, 2006.

[18] R. Kaushal et al. The costs and benefits of computerized physician order entry systems: a systematic review. *International Journal of Technology Assessment in Health Care*, 19 (4):652–663, 2003.

[19] J. Abarca et al. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. *Journal of Managed Care Pharmacy*, 10 (5):412–418, 2004.

[20] P. D. Hansten and J. R. Horn. *Drug interactions analysis and management*. Applied Therapeutics Inc., 2008.

[21] J. B. Beuscart et al. Automated detection of drug-drug interactions in medication review: evaluation in a french clinical setting. *Drug Safety*, 32(12):1067–1075, 2009.

[22] D. S. Wishart et al. Drugbank 5.0: a major update to the drugbank database for 2018. *Nucleic Acids Research*, 46(D1):D1074–D1082, 2018.

[23] T. L. Humphries et al. Evaluation of a community pharmacy-based medication therapy management program. *Pharmacotherapy*, 27(9):1243–1253, 2007.

[24] T. Roblek et al. Drug-drug interaction software in clinical practice: a systematic review. *European Journal of Clinical Pharmacology*, 71(2):131–142, 2015.

[25] P. L. Smithburger et al. A critical evaluation of clinical decision support for the detection of drug-drug interactions. *Expert Opinion on Drug Safety*, 11(2):171–182, 2012.

[26] P. Zhang et al. Label propagation prediction of drug-drug interactions based on clinical side effects. *Scientific Reports*, 7(1):12339, 2017.

[27] J. Huang et al. Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network. *PLoS Computational Biology*, 9(3): e1002998, 2013.

[28] Y. Zheng et al. A neural model for drug-drug interaction extraction from biomedical text. *BMC Bioinformatics*, 18(1):198, 2017.

[29] J. Y. Ryu, H. U. Kim, and S. Y. Lee. Deep learning improves prediction of drug-drug and drug-food interactions. *Proceedings of the National Academy of Sciences of the United States of America*, 115(18):E4304–E4311, 2018.

[30] Y. H. Feng et al. Dpddi: a deep predictor for drug-drug interactions. *BMC Bioinformatics*, 21(1):419, 2020.

[31] S. Vilar et al. Drug-drug interaction through molecular structure similarity analysis. *Journal of the American Medical Informatics Association*, 21(6):1066–1073, 2014.

[32] A. Gottlieb et al. Predict: a method for inferring novel drug indications with application to personalized medicine. *Molecular Systems Biology*, 8(1):592, 2012.

[33] G. Stanovsky et al. Recognizing mentions of adverse drug reaction in social media using knowledge-infused recurrent models. In *Proceedings of the 15th Conference of the European Chapter of the Association for Computational Linguistics*, volume 1, pages 142–151, 2017.

[34] S. M. Lundberg and S. I. Lee. A unified approach to interpreting model predictions. In *Advances in Neural Information Processing Systems*, volume 30, pages 4765–4774, 2017.

[35] N. Rohani and C. Eslahchi. Drug-drug interaction predicting by neural network using integrated similarity. *Scientific Reports*, 9(1):13645, 2019.

[36] Andreja Kastrin et al. Predicting potential drug-drug interactions on topological and semantic similarity features using statistical learning. *PLoS One*, 13(5):e0196865, 2018. doi: 10.1371/journal.pone.0196865.

[37] L. Dayer et al. Smartphone medication adherence apps: Potential benefits to patients and providers. *Journal of the American Pharmacists Association*, 53(2):172–181, 2013.

[38] E. M. Goldberg et al. Mobile health technology and adherence to treatment in patients with cardiovascular disease: A systematic review. *Telemedicine and e-Health*, 21(5): 366–372, 2015.

[39] H. Anglada-Martinez et al. Does mhealth increase adherence to medication? results of a systematic review. *International Journal of Clinical Practice*, 69(1):9–32, 2015.

[40] L. Whitehead and P. Seaton. The effectiveness of self-management mobile phone and tablet apps in long-term condition management: A systematic review. *Journal of Medical Internet Research*, 18(5):e97, 2016.

[41] S. Hamine et al. Impact of mhealth chronic disease management on treatment adherence

and patient outcomes: A systematic review. *Journal of Medical Internet Research*, 17 (2):e52, 2015.

[42] K. Santo et al. Medication reminder applications to improve adherence in coronary heart disease: A randomised clinical trial. *Heart*, 102(11):895–902, 2016.

[43] Y. Gandapur et al. The role of mhealth for improving medication adherence in patients with cardiovascular disease: A systematic review. *European Heart Journal - Quality of Care and Clinical Outcomes*, 2(4):237–244, 2016.

[44] M. H. Reckmann et al. Does computerized provider order entry reduce prescribing errors for hospital inpatients? a systematic review. *Journal of the American Medical Informatics Association*, 16(5):613–623, 2009.

[45] T. Roblek et al. Drug-drug interaction software in clinical practice: a systematic review. *European Journal of Clinical Pharmacology*, 71(2):131–142, 2015.

[46] N. Rohani and C. Eslahchi. Drug-drug interaction predicting by neural network using integrated similarity. *Scientific Reports*, 9(1):13645, 2019.

[47] R. Kaushal et al. The costs and benefits of computerized physician order entry systems: a systematic review. *International Journal of Technology Assessment in Health Care*, 19 (4):652–663, 2003.

[48] P. L. Smithburger et al. A critical evaluation of clinical decision support for the detection of drug-drug interactions. *Expert Opinion on Drug Safety*, 11(2):171–182, 2012.

[49] L. Dayer et al. Smartphone medication adherence apps: Potential benefits to patients and providers. *Journal of the American Pharmacists Association*, 53(2):172–181, 2013.

[50] K. Cresswell et al. Ten key considerations for the successful implementation and adoption of large-scale health information technology. *Journal of the American Medical Informatics and Decision Making*, 20(e1):e9–e13, 2013.

[51] L. Lamri et al. Healthcare system challenges and digital health opportunities in algeria. *International Journal of Healthcare Management*, 11(3):215–222, 2018.

[52] H. Benhalima and B. Chaudhry. Electronic health records adoption in developing coun-

tries: The case of algeria. *Health Policy and Technology*, 7(4):382–390, 2018.

[53] J. B. Beuscart et al. Automated detection of drug-drug interactions in medication review: evaluation in a french clinical setting. *Drug Safety*, 32(12):1067–1075, 2009.

[54] M. Atek et al. Healthcare information systems interoperability in algeria: Current state and challenges. *International Journal of Medical Informatics*, 107:1–8, 2017.

[55] International Telecommunication Union. Ict statistics for algeria. Technical report, ITU World Telecommunication/ICT Indicators Database, 2021.

[56] F. Mostefai et al. Digital transformation in algerian healthcare: Opportunities and challenges. *Journal of Healthcare Management*, 64(2):89–102, 2019.

[57] GSMA Intelligence. The mobile economy: Middle east and north africa 2021. Technical report, GSMA Association, 2021.

[58] Regulation on medical devices and health technologies in algeria. Official Journal of the People's Democratic Republic of Algeria, No. 42, 2020.

[59] H. Benhalima and B. Chaudhry. Electronic health records adoption in developing countries: The case of algeria. *Health Policy and Technology*, 7(4):382–390, 2018.

[60] J. B. Beuscart et al. Automated detection of drug-drug interactions in medication review: evaluation in a french clinical setting. *Drug Safety*, 32(12):1067–1075, 2009.

[61] A. Benyahia et al. Public health and the legal regulation of the pharmaceutical industry in algeria. *Pan African Medical Journal*, 44:89, 2023.

[62] L. Lamri et al. Healthcare system challenges and digital health opportunities in algeria. *International Journal of Healthcare Management*, 11(3):215–222, 2018.

[63] T. Roblek et al. Drug-drug interaction software in clinical practice: a systematic review. *European Journal of Clinical Pharmacology*, 71(2):131–142, 2015.

[64] G. D. Schiff et al. A prescription for improving drug formulary decision making. *PLoS Medicine*, 8(5):e1001035, 2011.

[65] Jae Yong Ryu, Hyun Uk Kim, and Sang Yup Lee. Deep learning improves predic-

tion of drug–drug and drug–food interactions. *Proceedings of the National Academy of Sciences of the United States of America*, 115(18):E4304–E4311, 2018. doi: 10.1073/pnas.1803294115.

[66] International Telecommunication Union. Ict statistics for algeria. Technical report, ITU World Telecommunication/ICT Indicators Database, 2021.

[67] M. B. Buntin et al. The benefits of health information technology: a review of the recent literature shows predominantly positive results. *Health Affairs*, 30(3):464–471, 2011.

[68] Insights10. Algeria digital health market analysis report 2022 to 2030. Market analysis report on digital health compensation and coverage in Algeria, 2022.

[69] A. Gottlieb, G. Y. Stein, E. Ruppin, and R. Sharan. Predict: a method for inferring novel drug indications with application to personalized medicine. *Mol Syst Biol*, 7:496, 2011.

[70] D. M. Roden, G. R. Wilkinson, A. J. Wood, and R. L. Woosley. Drug therapy: disposition kinetics of drugs. *N Engl J Med*, 319(20):1349–1358, 1988.

[71] I. Cascorbi. Drug interactions–principles, examples and clinical consequences. *Dtsch Arztebl Int*, 109(33-34):546–555, 2012.

[72] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*, 46(1-3):3–26, 2001.

[73] D. A. Smith, Di L, and E. H. Kerns. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov*, 9(12):929–939, 2010.

[74] N. H. Holford and L. B. Sheiner. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. *Clin Pharmacokinet*, 6(6): 429–453, 1981.

[75] D. R. Abernethy, D. J. Greenblatt, and R. I. Shader. Treatment of diazepam withdrawal syndrome with propranolol. *Ann Intern Med*, 94(3):354–355, 1981.

[76] International Transporter Consortium, K. M. Giacomini, S. M. Huang, et al. Membrane transporters in drug development. *Nat Rev Drug Discov*, 9(3):215–236, 2010.

[77] S. Shugarts and L. Z. Benet. The role of transporters in the pharmacokinetics of orally administered drugs. *Pharm Res*, 26(9):2039–2054, 2009.

[78] L. Z. Benet and B. A. Hoener. Changes in plasma protein binding have little clinical relevance. *Clin Pharmacol Ther*, 71(3):115–121, 2002.

[79] L. N. Sansom and A. M. Evans. What is the true clinical significance of plasma protein binding displacement interactions? *Drug Saf*, 12(4):227–233, 1995.

[80] U. M. Zanger and M. Schwab. Cytochrome p450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther*, 138(1):103–141, 2013.

[81] T. Lynch and A. Price. The effect of cytochrome p450 metabolism on drug response, interactions, and adverse effects. *Am Fam Physician*, 76(3):391–396, 2007.

[82] L. E. Hines and J. E. Murphy. Potentially harmful drug-drug interactions in the elderly: a review. *Am J Geriatr Pharmacother*, 9(6):364–377, 2011.

[83] P. D. Hansten and J. R. Horn. *Drug Interactions Analysis and Management*. Facts and Comparisons, 2010.

[84] G. Murtaza, M. Y. Khan, S. Azhar, et al. Assessment of potential drug-drug interactions and its associated factors in the internal medicine ward. *Saudi Pharm J*, 24(1):16–21, 2016.

[85] Y. Feng, Q. Wu, Y. Peng, et al. Ddinter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. *Nucleic Acids Res*, 50(D1): D1200–D1207, 2022.

[86] P. L. Smithburger, S. L. Kane-Gill, and A. L. Seybert. Drug-drug interactions in the cardiothoracic intensive care unit. *Crit Care Med*, 38(2):595–603, 2010.

[87] M. Abdelmoneem, M. A. Mahmoud, and X. Fang. The prevalence and severity of potential drug-drug interactions in internal medicine ward at soba teaching hospital. *Drug Healthc Patient Saf*, 15:153–166, 2023.

[88] D. S. Wishart, C. Knox, A. C. Guo, et al. Drugbank: a comprehensive resource for

in silico drug discovery and exploration. *Nucleic Acids Res*, 34(Database issue):D668–D672, 2006.

[89] D. S. Wishart, Y. D. Feunang, A. C. Guo, et al. Drugbank 6.0: the drugbank knowledgebase for 2024. *Nucleic Acids Res*, 52(D1):D1265–D1275, 2024.

[90] S. Kim, J. Chen, T. Cheng, et al. Pubchem in 2021: new data content and improved web interfaces. *Nucleic Acids Res*, 49(D1):D1388–D1395, 2021.

[91] S. Kim, P. A. Thiessen, E. E. Bolton, et al. Pubchem substance and compound databases. *Nucleic Acids Res*, 44(D1):D1202–D1213, 2016.

[92] U.S. Food and Drug Administration. Drugs@fda: Fda-approved drug products. `https://www.accessdata.fda.gov/scripts/cder/daf/`.

[93] National Center for Biotechnology Information. Pubmed. `https://pubmed.ncbi.nlm.nih.gov/`.

[94] WHO Collaborating Centre for Drug Statistics Methodology. Atc/ddd index. `https://www.whocc.no/atc`$_d$`dd`$_i$`ndex/`.

[95] Indiana University School of Medicine. Drug interactions: Cytochrome p450 drug interaction table. `https://drug-interactions.medicine.iu.edu/`.

[96] K. M. Morrissey, X. Wen, S. J. Johns, et al. The ucsf-fda transportal: a public drug transporter database. *Clin Pharmacol Ther*, 92(5):545–546, 2012.

[97] I. Cascorbi. Drug interactions–principles, examples and clinical consequences. *Dtsch Arztebl Int*, 109(33-34):546–555, 2012.

[98] D. A. Smith, Di L, and E. H. Kerns. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov*, 9(12):929–939, 2010.

[99] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*, 46(1-3):3–26, 2001.

[100] L. Chen, Y. Li, Q. Zhao, et al. Admet evaluation in drug discovery. 10. predictions of

p-glycoprotein inhibitors using recursive partitioning and naive bayesian classification techniques. *Mol Pharm*, 8(3):889–900, 2011.

[101] D. M. Roden, G. R. Wilkinson, A. J. Wood, and R. L. Woosley. Drug therapy: disposition kinetics of drugs. *N Engl J Med*, 319(20):1349–1358, 1988.

[102] L. Magro, U. Moretti, and R. Leone. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. *Expert Opinion on Drug Safety*, 11(1):83–94, 2012.

[103] N. H. Holford and L. B. Sheiner. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. *Clin Pharmacokinet*, 6(6): 429–453, 1981.

[104] J. Yu, Z. Zhou, J. Tay-Sontheimer, et al. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the us food and drug administration between 2013 and 2016. *Drug Metab Dispos*, 46(6):835–845, 2018.

[105] International Transporter Consortium, K. M. Giacomini, S. M. Huang, et al. Membrane transporters in drug development. *Nat Rev Drug Discov*, 9(3):215–236, 2010.

[106] S. Shugarts and L. Z. Benet. The role of transporters in the pharmacokinetics of orally administered drugs. *Pharm Res*, 26(9):2039–2054, 2009.

[107] M. J. Zamek-Gliszczynski, K. A. Hoffmaster, K. Nezasa, et al. Integration of hepatic drug transporters and phase ii metabolizing enzymes: mechanisms of hepatic and biliary clearance of acetaminophen. *Clin Pharmacol Ther*, 78(1):13–27, 2005.

[108] L. Z. Benet and B. A. Hoener. Changes in plasma protein binding have little clinical relevance. *Clin Pharmacol Ther*, 71(3):115–121, 2002.

[109] L. N. Sansom and A. M. Evans. What is the true clinical significance of plasma protein binding displacement interactions? *Drug Saf*, 12(4):227–233, 1995.

[110] U. M. Zanger and M. Schwab. Cytochrome p450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther*, 138(1):103–141, 2013.

[111] T. Lynch and A. Price. The effect of cytochrome p450 metabolism on drug response, interactions, and adverse effects. *Am Fam Physician*, 76(3):391–396, 2007.

[112] R. Böhm, L. von Hehn, T. Herdegen, et al. Openvigil fda - inspection of u.s. american adverse drug events pharmacovigilance data and novel clinical applications. *PLoS One*, 7(3):e33859, 2012.

[113] F. Cheng and Z. Zhao. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. *J Am Med Inform Assoc*, 21(e2):e278–e286, 2014.

[114] S. M. Huang, J. M. Strong, L. Zhang, et al. New era in drug interaction evaluation: Us food and drug administration update on cyp enzymes, transporters, and the guidance process. *J Clin Pharmacol*, 48(6):662–670, 2008.

[115] D. N. Juurlink, M. Mamdani, A. Kopp, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. *JAMA*, 289(13):1652–1658, 2003.

[116] A. Kastrin, P. Ferk, and B. Leskošek. Predicting potential drug-drug interactions on topological and semantic similarity features using statistical learning. *PLoS One*, 13(5): e0196865, 2018.

[117] S. Vilar, C. Friedman, and G. Hripcsak. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. *Brief Bioinform*, 19(5):863–877, 2018.

[118] L. Zhang, K. S. Reynolds, P. Zhao, and S. M. Huang. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. *Toxicol Appl Pharmacol*, 243(2): 134–145, 2010.

[119] D. A. Smith, Di L, and E. H. Kerns. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov*, 9(12):929–939, 2010.

[120] U. M. Zanger and M. Schwab. Cytochrome p450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther*, 138(1):103–141, 2013.

[121] K. M. Giacomini, S. M. Huang, D. J. Tweedie, et al. Membrane transporters in drug

development. *Nat Rev Drug Discov*, 9(3):215–236, 2010.

[122] C. Palleria, A. Di Paolo, C. Giofrè, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. *J Res Med Sci*, 18(7):601–610, 2013.

[123] Vladimir N Vapnik. *The Nature of Statistical Learning Theory*. Springer-Verlag, New York, 1995. ISBN 978-0-387-94559-0. doi: 10.1007/978-1-4757-2440-0.

[124] Kevin P Murphy. Naive bayes classifiers. *University of British Columbia*, 18:60, 2006.

[125] David W Hosmer Jr, Stanley Lemeshow, and Rodney X Sturdivant. *Applied Logistic Regression*. John Wiley & Sons, Hoboken, NJ, 3rd edition, 2013. ISBN 978-0-470-58247-3. doi: 10.1002/9781118548387.

[126] Tianqi Chen and Carlos Guestrin. Xgboost: A scalable tree boosting system. In *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, pages 785–794, San Francisco, CA, 2016. ACM. doi: 10.1145/2939672.2939785.

[127] Guolin Ke, Qi Meng, Thomas Finley, Taifeng Wang, Wei Chen, Weidong Ma, Qiwei Ye, and Tie-Yan Liu. Lightgbm: A highly efficient gradient boosting decision tree. *Advances in Neural Information Processing Systems*, 30:3146–3154, 2017.

[128] Yann LeCun, Yoshua Bengio, and Geoffrey Hinton. Deep learning. *Nature*, 521(7553): 436–444, 2015. doi: 10.1038/nature14539.

[129] Sepp Hochreiter and Jürgen Schmidhuber. Long short-term memory. *Neural Computation*, 9(8):1735–1780, 1997. doi: 10.1162/neco.1997.9.8.1735.

[130] Jacob Devlin, Ming-Wei Chang, Kenton Lee, and Kristina Toutanova. Bert: Pre-training of deep bidirectional transformers for language understanding. *arXiv preprint arXiv:1810.04805*, 2018.